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ABSTRACT 
 
Glioblastoma (GBM) is the most malignant form of glioma with patients having a poor 
survival rate of 15 months post diagnosis. Metagenomics has shown that GBM is a 
heterogeneous disease consisting of four genetic subtypes (Proneural, Classical, 
Mesenchymal and Neural) characterised by diverse mutations and differential sensitivity to 
treatment. Understanding how these subtypes interact to promote tumour survival is 
imperative for the design of targeted treatments to treat the whole tumour and not specific 
subtypes. Previous research used adherent monolayer cultures however these do not 
accurately portray the complex microenvironment and 3D cell-cell interactions observed in 
vivo This study aimed to develop a 3D culture model, using 3 cell lines representative of the 
GBM subtypes grown as multicellular spheroids. Subtype interactions were observed using 
confocal microscopy and preferential subtype locations were seen within the polyclonal 
spheroid. Spheroids were treated with chemotherapy agent, Temozolomide (TMZ), and 
observations showed that the Mesenchymal subtype proliferated and relocated to the spheroid 
centre, potentially promoting spheroid survival. This study provides a suitable in vitro culture 
model of GBM heterogeneity, which can be further developed to improve the effectiveness of 
future research and the opportunity for the development of more targeted treatments. 
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1. INTRODUCTION 
1.1 Glioblastoma 
Glioblastoma (GBM) is the most severe type of glioma, a class of malignant brain tumours 
derived from glial cells
[1, 2]
. The cancer has a significantly poor survival prognosis of less than 
one year from time of diagnosis
[3]
. Even with multimodal treatment strategies, the median 
survival time is around 15 months, with as little as 3-5% survival over 36 months
[4]
. Despite 
brain tumours affecting more people under 40 years old than any other cancer, less than 2% of 
cancer research funding is dedicated to brain tumour research
[5]
. Due to the severity of this 
condition, it is imperative that further research is conducted into the causes of GBM and 
potential treatments. 
 
Gliomas have been histologically classified according to the World Health Organisation 
(WHO) into astrocytomas, oligodendrogliomas and mixed oligoastrocytomas
[2, 6]
. These 
tumours are then graded according to severity based on information obtained from a tumour 
biopsy
[2]
.
 
Low-grade gliomas (LGGs), designated as grades I/II, are slow growing but may 
progress to more aggressive tumours
[2]
. Grade III/IV tumours are fast-progressing, high-grade 
gliomas (HGGs), with the most malignant grade IV glioblastoma accounting for 82% of 
gliomas
[7]
. Around 90% of GBMs are believed to arise de novo (primary GBM)
[8, 9] 
i.e. 
without any clinical evidence of a preceding lower grade tumour, whereas 10% arise from 
progression from LGGs (secondary GBM)
[9, 10]
. Genetic studies have shown that primary and 
secondary tumours have distinct genetic profiles that largely differ from each other
[8, 11]
, 
(figure 1). 
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Figure 1: The genetic pathways of Gliomas (Ohgaki et al., 2013 
[8]
). Schematic 
documenting the genetic mutations involved in the generation of primary and 
secondary glioblastomas. Note that despite both originating from glial progenitor 
cells, primary and secondary GBM have separate, distinctive differences in the 
mutations present and also the time course of tumour progression. 
 
 
GBM has a significant impact on the quality of life of both the patient and their relatives and 
since primary GBM is most common in elderly patients
[2, 8]
, it is thought that GBM incidence 
could rise with an ever-increasing ageing population
[7]
. This only emphasises that more 
research needs to be conducted to be able to better diagnose and develop improved treatment 
strategies for GBM in the near future. 
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1.2 Importance of Tumour Heterogeneity and Genetic Subtypes in Glioma 
Tumour heterogeneity is important in glioma research as different cells have characteristically 
different phenotypes with regards to survival and response to treatment
[12]
. Tumours are not 
solely comprised of homotypic cells but are more commonly an ensemble of different cell 
types that differ in genetic morphology, which is important for tumour invasiveness, 
metastatic behaviour and ultimately drug resistance
[13]
. Tumours vary not only between 
patients, but also within the same organ, known as inter-tumour heterogeneity
[14]
. Cells from 
different locations within a tumour have also been shown to portray a different genetic profile 
(intra-tumour heterogeneity)
[14]
. Defining these genetic profiles can assist in not only 
diagnosing glioma but also in predicting patient’s response to therapy[15]. 
 
Development of next generation sequencing technologies over the past decade
[16]
, has allowed 
an integrated approach, using metagenomic and metatranscriptomic analyses
[17]
, to explore 
heterogeneity in GBM
[1]
. The Cancer Genome Atlas defined four genetic subtypes (Verhaak 
Classification), which allowed for the first time to categorise the extensive inter-tumoural 
heterogeneity observed in GBM
[4, 18, 19]
, table 1.  
 
 
 
 
 
 
 
 
  
 
4 
 Proneural Classical Mesenchymal Neural 
Amplifications PDGFRA (4q12) 
EGFR (97%) 
Chromosome 7 
MET 
CDK6 
 
Mutations 
IDH1 point 
mutations (R132) 
PDGFRA 
TP53 
PIK3R1/CA 
EGFR 
 
NF1 
PTEN 
RB1 
 
 
Deletions  
CDKN2A/2B 
Chromosome 10 
loss 
Homozygous 
deletion NF1 
 
Gene 
Expression 
OLIG2 
NKX2-2 
CDKN1A 
NES 
Notch 
Sonic Hedghog 
NF1 
CH13L1 
MET 
NEFL 
GABRA1 
SYT1 
SLC12AS 
Gene 
Signature 
Oligodendrocytic Astrocytic Cultured astroglial 
Enrichment in 
neuronal genes 
 
Table 1: Genetic alterations classifying Glioma subtypes. Table 1 shows the 
gene amplifications, mutations, deletions and expression characterising four GBM 
subtypes as defined by the Verhaak Classification system.  
 
 
The Proneural subclass characteristically display a point mutation in the isocitrate-
dehydrogenase 1 (IDH1) gene, the earliest detectable mutation in LGGs
[8]
 and consequently 
seen in 80% of secondary GBMs, compared to 5% of primary GBMs
[10, 20]
. Mutations in 
IDH1 are generally associated with an increase in the overall survival, after combined surgery 
and radiotherapy, from an average of 11.3 months to 27.1 months
[20]
. Thus, IDH1 mutations 
are a strong predictor of a more favourable prognosis and a highly selective molecular marker 
of secondary GBM. The Classical subgroup is defined by high-level amplification of 
epidermal growth factor receptors (EGFRs) present in 40-50% of glioblastomas
[21]
, 
predominately primary GBMs, but also in a minority of secondary GBMs
[9]
. The 
Mesenchymal subgroup is distinguished by homozygous deletions/mutations in the 
neurofibromin1 gene, NF1
[19]
. Other mesenchymal markers are also highly expressed 
corresponding to a higher level of necrosis and inflammation
[19]
. The Neural subtype is 
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categorised by expression of neuronal markers such as NEFL, SYT1 and GABRA1 and is 
most similar to normal brain tissue
[19]
. 
 
A study conducted by Sottoriva et al., 2013
[12]
 showed that in 6 out of 10 tumours analysed, 
fragments taken from the same tumour were classified into at least 2 subgroups, suggesting 
that clonal interactions are potentially important for tumour survival. Selective pressures such 
as chemotherapy treatment, allow for populations of tumour cells that have acquired genetic 
alterations to survive, rendering them resistant to that treatment
[12, 22]
. The resistant tumour 
cells can co-operate with other subtypes present and even alter the tumour microenvironment 
to facilitate overall survival
[13]
. EGFR mutations have shown to confer resistance to treatment 
and have actually been detected before treatment has commenced
[14, 23]
. Inter-clonal co-
operativity and mutualistic interactions are thought to a method of maintaining heterogeneity 
and promoting tumour growth
[14, 24]
 consequently leading to recurrence
[25]. 
Despite this, there 
is optimism that a stratified treatment approach could potentially be derived according to the 
patient subtype to retard inter-clonal co-operativity
[14]
. It is therefore imperative that tumour 
heterogeneity and clonal interactions are further investigated.  
 
1.3 Treatment Strategy  
Treating GBM is problematic since tumour cells are highly aggressive and particularly 
resistant to therapy
[26]
. This becomes a significant issue because invasive and irradiating 
treatment can consequently damage surrounding healthy tissue, which the brain cannot 
adequately repair posing an important question of the necessity of aggressive treatments.   
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The first line of treatment for glioma is surgical resection. Tumours are first graded in 
malignancy with the highest grade being reported, however many reports discussing the 
heterogeneous nature of gliomas suggest single biopsies underestimate the mutational 
heterogeneity, giving a misleading prognosis
[27]
. A clinical study
[28, 29]
 has shown that 
complete tumour resection is needed to benefit survival however, unfortunately due to high 
invasion into surrounding tissue, complete resection is often impossible
[1]
.  
 
Following surgery, the patient undergoes successive rounds of combined radiation therapy 
(RT) and chemotherapy. Stupp et al., 2005
[3]
 investigated the benefit of combined RT and 
chemotherapy and consequently showed a significant increase in the 2-year survival rate from 
10.4% with radiotherapy alone to 26.5% when treated with RT and chemotherapy in 
combination. The current chemotherapy reagent is Temozolomide (TMZ) which, following 
administration, methylates DNA at positions N
7
 and O
6
 of guanine residues and O
3
 of adenine 
residues
[30]
. The mismatch repair (MMR) system, designed to repair DNA, fails at 
incorporating a complementary base pair to the methylated residues, consequently inducing 
DNA lesions along the strand. These lesions accumulate inhibiting successful DNA 
replication, triggering tumour cell apoptosis
[31]
. Some tumour cells however are resistant to 
TMZ-induced damage. The O
6
-methylguanine DNA methyltransferase (MGMT) gene 
encodes DNA repair enzyme that specifically removes methyl groups present at the O
6
 
position of guanine, thus repairing TMZ-induced adducts
[32]
. However, epigenetic silencing of 
the MGMT promoter region via methylation, apparent in approximately 45-50% of GBM 
patients
[33-35]
, prevents expression of MGMT, therefore restoring sensitivity to TMZ. Hence, 
MGMT promoter methylation has shown to greatly benefit patients treated with TMZ
[36]
, as 
seen in a clinical study conducted by Hegi et al., 2005
[37]
. 
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Treatment stratification is particularly important, as different glioma subtypes have been 
shown to respond differently to chemotherapy. It has been shown that the Proneural subtype 
does not respond to aggressive treatment
[19]
. Similarly, patients that do not have methylated 
MGMT undergo the same aggressive procedure even though it provides no additional benefit 
to their survival
[28, 37]
. Considering chemotherapy cycles are severely debilitating and costs the 
NHS around £12,000 per patient
[38]
, both health organisations and patients will benefit from 
the ability to characterise different forms of GBM, providing a more targeted and effective 
approach to treatment.  
 
1.4 Investigating Glioma Heterogeneity in vitro 
1.4.1 Adherent monolayer cultures  
In vitro cell culture has proved to be an invaluable technique for investigating many cellular 
processes
[39, 40]
. Previous research has utilised an adherent monolayer technique, however this 
has recently been questioned as to whether this method accurately represents in vivo 
observations
[40]
. 2-dimensonal (2D) cultures do not accurately represent the 
microenvironment and architecture present in intact tissue
[41]
 which are important for 
processes such as proliferation, adhesion and migration
[42]
 that influence cell infiltration and 
invasion. The many parameters that dynamically impact these factors can be seen in figure 2. 
Consequently, a more biologically relevant model of cell culture is required to provide an 
increased insight into many cellular processes
[43]
. 
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Figure 2: Environmental factors influencing cell growth and behaviour 
(Yamada et al.,
[44]
). There are many aspects that affect the spatial and temporal 
growth of cells, which is absent in adherent monolayer cultures. 3D culture 
models better represent in vivo cell behaviour since these influential factors are 
introduced. Tumour cells are known be dynamically influenced by the 
surrounding microenvironment and neighbouring host cells, ultimately 
manipulating tumour growth, invasiveness and malignancy. The 
microenvironment is not a heterogeneous environment and fluctuations in factors 
such as oxygen pressure, growth factors and density of blood vessels can allow 
selective pressures on different mutations and thus manifest different tumour 
phenotypes
[14, 24]
 and responses to therapy. 
 
1.4.2 3D Cell Culture  
3-dimensional (3D) cell culture was first described more than 40 years ago by Sutherland et 
al., 1971
[45]
 who cultured Chinese hamster V79 lung cells in suspension using spinner flasks 
and noted these cells formed multicellular aggregates that resembled the small nodules seen in 
human carcinomas. Since, many methods have been developed including the hanging-drop 
method
[46]
, microfluidic channels
[39]
, reconstituted basement membrane (Matrigel)
[42] 
and the 
liquid-overlay technique. Yuhas et al., 1977
[47, 48]
 described this technically simple method of 
seeding cell suspensions onto a thin layer of agarose or gelatinous material. This then allows 
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cells to spontaneously aggregate rather than adhere to the culture vessel due to the fact that 
the adhesive forces between the cells is greater than that onto which they are seeded
[43]
. The 
cellular aggregates that form are known as multicellular spheroids and provide a 3D in vitro 
model that allows spatial and temporal organisation of cell growth
[39, 40]
. 
 
Tumour spheroids display similar growth kinetics and morphological characteristics to that of 
in vivo tumours
[49, 50]
. The size and growth rate largely depends on cell type however an 
average size of more than 100-150 µm is generally accepted as a spheroid. As the spheroid 
grows in size, a nutrient, metabolite and oxygen concentration gradient is generated across the 
spheroid which establishes spatially separate regions of cells that are comparably observed 
within in vivo tumours
[43]
. These three structurally distinct regions involve an outer peripheral 
layer of proliferating cells, an inner core of tightly packed viable but hypoxic and quiescent 
cells and a central core of necrotic cells, which have died from deprivation of oxygen and 
nutrients
[51, 52]
 (figure 3).  
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Figure 3: Multicellular spheroid characteristics (based on Ota and Miki, 
2012
[53]
). Adherent monolayers do not exhibit the high biological complexity, 
increased cell density and cellular connections as observed in multicellular 
spheroids. Upon growth of 3D spheroids, a steep oxygen, glucose, nutrient and 
metabolite concentration gradient is generated which results in a stratified 
arrangement of cells. The outer layer consists of viable and proliferating cells, 
underneath is a layer of quiescent and hypoxic layer of cells and in the central 
region of the spheroid is generally a core of necrotic and dead cells that have been 
deprived of oxygen and other nutrients needed for survival.  
 
 
Many studies have used homotypic spheroid models, for investigation into influence of 
metabolic and oxygen gradients on therapeutic treatments
[54]
.  However, it is becoming 
increasingly popular to introduce other interacting cell types to generate a heterotypic 
polyclonal co-culture. This provides a more representative model since many tumours are 
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known to exude heterogeneity, as previously discussed. By providing a 3D model of different 
cell types, the diverse cellular interactions, localisations and co-dependencies can be 
investigated.  
 
This 3D spheroid co-culture method can be applied to create an in vitro model of glioma. De 
Witt Hamer et al., 2008
[55]
 analysed the genetic profile of glioma 2D monolayer cultures, 
spheroid cultures and cultures derived from primary tumours, and showed that the genomic 
profile of glioma subtypes is preserved in 3D multicellular spheroids however lost in short-
term 2D culture. By being able to recapitulate this heterogeneity seen within GBM using 
known proportions of glioma cell lines representative of the different subtypes, the clonal 
relationships can be analysed in a controlled manner, which has yet to be investigated
[14, 24]
. 
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2. AIMS AND HYPOTHESES 
2.1 Aims  
The aims of this project were to: 
 To develop a method for 3D culturing of polyclonal spheroids to provide a more 
representative in vitro model of GBM. 
 To use this model to assess the heterogeneity, morphology and subtype interactions of 
three glioma cell lines representative of the different GBM subtypes.  
 To investigate the different responses to chemotherapy treatment (TMZ) in each of the 
subtypes both individually and also within the polyclonal spheroid model. 
 
2.2 Hypotheses 
It was hypothesised that the three subtypes will exhibit differential morphology when grown 
as spheroids with a stratified arrangement of cells, including an apparent necrotic core due to 
central oxygen and nutrient deprivation. It is also hypothesised that the subtypes will have 
diverse locations within the polyclonal spheroid that can potentially contribute to overall 
spheroid viability. Furthermore, upon addition of chemotherapy reagent Temozolomide, the 
different cell lines will exhibit a varied sensitivity, as seen in patient tumours
[19]
, but could 
potentially co-operate when grown as a polyclonal spheroid to permit survival.  
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3. MATERIALS AND METHODS 
 
3.1 Glioma Cell Lines 
 
Three different cell lines, U343-YFP, U373-RFP and U87 IDH1-Mutant-GFP, were selected 
to investigate the aims outlined in section 2.1. Table 2 shows the characteristics of each cell 
line.  
 
Cell Line 
U87 IDH1-
Mutant-GFP 
U343-YFP U373-RFP 
Representative 
Subtype 
Proneural Classical Mesenchymal 
Representative 
Characteristic 
Mutation in IDH1 
(R132H) 
High EGFR 
expression 
Low NF1 expression 
Fluorescent tag 
Green Fluorescent 
Protein 
Yellow Fluorescent 
Protein 
Red Fluorescent 
Protein 
 
Table 2: Glioma cell line characteristics. Three glioma cell lines were selected, 
each with a defining characteristic best representative of a different GBM subtype. 
The U87 cell line had been engineered to overexpress mutant IDH1, which is 
characteristically seen in the Proneural GBM subtype. The U343-YFP cell line 
was selected as it had high EGFR expression therefore making it best 
representative of the Classical subtype. Finally U373-RFP cells were designated 
to be best representative of the Mesenchymal GBM subtype due to low NF1 
expression. Furthermore, each of the cell lines had been engineered to 
endogenously express a fluorescent protein, for identification during confocal 
microscopy. In addition, a fourth cell line, U87 IDH1-WT-GFP, was used as a 
control for U87 IDH1-Mutant-GFP.   
 
   
It has been shown that the IDH1 mutation cannot be propagated in culture
[56]
 and so the U87 
line had been previously generated to stably overexpress IDH1
R132H
 or IDH1
WT
 
[57]
. 
Additionally, each cell line had been formerly engineered within the laboratory to 
endogenously express a fluorophore allowing for identification via confocal microscopy. Cell 
lines were sorted by fluorescent-activated cell sorting (FACS) to distinguish the highest 
fluorophore expressing cells so that these cells could be selected and maintained in culture. 
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3.2 Cell Culture 
3.2.1 Adherent Monolayer Culture  
All glioma cells lines were cultured in Dulbecco's Modified Eagle Medium (DMEM; Hyclone 
Thermo scientific, SH30285.01) supplemented with 10% foetal bovine serum (FBS; Hyclone 
Thermo Scientific, SV30160.03) and 2 mM L-Glutamine at 37C, 21% O2 and 5% CO2. Cells 
were subject to routine mycoplasma testing in case of contamination.  
 
3.2.2 Spheroid Cell Culture  
To obtain spheroids, individual cell lines (listed above) were grown on 0.5% agarose plates 
using the liquid-overlay method
[47]
. Agarose plates were made using 0.5% low-melting point 
agarose (LMP; Promega, V2111) in DMEM which had been pre-heated to 60°C. 10mls of 
0.5% agarose/DMEM solution was then plated onto a 10 cm sterile petri dish and left to set. 
Once cells had been trypsinised and counted using Countess® Automated Cell Counter (Life 
Technologies), 1x10
6
 cells of each cell line was seeded onto individual 10 cm 0.5% agarose 
plate. The plates were then topped up to 20 ml with DMEM creating an aqueous overlay in 
which 3D spheroids could develop. The plates were left undisturbed for 2-4 days (37°C, 5% 
CO2). U87 IDH1-WT-GFP and U87 IDH1-Mutant-GFP lines formed large multicellular 
spheroids within 2 days, before embedded into the 0.5% agarose layer. The U343-YFP and 
U373-RFP spheroids took 3-4 days to form. Polyclonal spheroids were generated by mixing 
equal number of cells (1x10
6
 cells) from U87 IDH1 Mutant-GFP, U343-YFP and U373-RFP 
lines in a total 20 ml medium. Spheroids were left undisturbed for 3 days (37°C, 5% CO2). 
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3.3 Spheroid Immunocytochemistry (ICC) 
Spheroids were transferred and filtered through a 40 µm cell strainer to retain any spheroids 
above this size. The cell strainer containing the spheroids was then inverted over a conical 
tube and washed with phosphate-buffered saline (PBS) to collect the spheroids. 1 ml of PBS 
containing the spheroids was then transferred to a microcentrifuge tube and cells were stained 
with either Pimonidazole (PIMO) or hypoxia-inducible factor 1 (HIF-1) to act as markers 
for hypoxia. 
 
PIMO staining was achieved using a Hydroxyprobe™-1 kit (Hydroxyprobe, Burlington MA, 
USA). Pimonidazole-HCL (200 μM) was added to spheroids in PBS and incubated (37°C, 1 
hour). Afterwards, or if not staining with PIMO, spheroids were subject to 10% formalin 
fixation for 1 hour at room temperature (RT). Following fixation, spheroids were centrifuged 
(0.8 rpm, 1 minute) and formalin was removed by aspiration. Spheroids were then subjected 
to permeabilisation using 250 µl 0.1% Triton-X-100 in PBS (20 minutes, RT). The 0.1% 
Triton-X-100-PBS solution was aspirated following centrifugation (0.8 rpm, 1 minute) and 
primary antibody was added to spheroids and kept at 4°C in the dark overnight. For PIMO 
staining, the primary antibody was 1:400 dilution of IgG1 mouse monoclonal antibody in 
PBS-0.5% Tween (PBS-T). For HIF-1 staining, purified mouse anti-human HIF-1α (BD 
Transduction, 610959) was used at 1:50 dilution in 0.5% BSA, PBS-T. Prior to addition of 
HIF-1α, spheroids were blocked in 5% BSA, PBS-T for 1 hour.  
 
After overnight incubation, the primary antibody was removed and anti-mouse IgG (H+L) 
DyLight 649 fluorescent secondary antibody (Vector labs, DI-2649) was added at a 1:100 
dilution in PBS-T (2 hours, RT). Spheroids were centrifuged (0.8 RPM, 1 min) and 500µl of 
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PBS was added. To stain for DNA, 1 drop of Hoechst 33342 (NucBlue® live cell stain ready 
probes™, Life Tech, R37605) dye was added for 20 minutes at RT. Following this, 250µl of 
spheroids were transferred to 1 well on an 8 well chamber slide and 200µl of 1% LMP 
agarose/PBS was added on top.  
 
3.4 Confocal Microscopy  
 
3.4.1 Acquisition Parameters 
 
A Zeiss LSM-510 confocal microscope was used to visualise the morphology and clonal 
interactions of the fluorescently labelled, agarose-embedded spheroids. The acquisition 
parameters used are shown in table 3.  
 
Fluorophore 
Hoechst-
33342 
GFP YFP RFP 
DyLight -
649 
Excitation 
Laser 
343 488 488 543 633 
Fluorophore 
Spectral Range 
(nm) 
Exmax- 343 
Emmax- 483 
Exmax- 488 
Emmax- 509 
Exmax- 514 
Emmax-527 
Exmax- 555 
Emmax- 584 
Exmax- 654 
Emmax- 673 
Lens 20x EC Plan-Neofluar objective 
Pinhole 
Optical size (monoclonals) 
1.8 Airy Units (polyclonals) 
Gain Adjusted per channel to avoid saturation in pixel intensity 
Resolution 512 x 512 
Scan speed 5 
Data Depth 12 bit 
 
 
Table 3: Confocal microscopy parameters. Table showing the specific 
parameters of the confocal microscope used for imaging the monoclonal and 
polyclonal spheroids. A 2D image was taken approximately mid-way through the 
spheroid, where the necrotic core was visible. 
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3.4.2 Imaging Polyclonal Spheroids 
Imaging of the polyclonal spheroids required application of a computer algorithm because the 
emission spectra from GFP and YFP fluorophores have high spectral overlap (figure 4). 
Therefore it was not possible to distinguish clearly between the fluorophores and the resulting 
image showed signal bleed through from one fluorophore into the detection channel of the 
other fluorophore.  
 
 
 
 
Figure 4: Excitation and emission spectra of common fluorescent proteins 
(Olympus
[58]
). Image shows excitation and emission wavelengths for common 
fluorescent proteins. It is apparent that GFP and YFP fluorophores have very 
close excitation and emission maximum values resulting in spectral overlap. It is 
therefore difficult to distinguish between the fluorescence from fluorophores 
when imaged in combination.  
 
 
A process called emission fingerprinting (figure 5) was employed to resolve the fluorescent 
contribution from each fluorophore
[59]
. Spheroids were first imaged with only one fluorophore 
present and an emission spectrum was saved as a reference in a spectral database. The 
lambda-unmixing programme was then applied when imaging the fluorophores in 
combination. A lambda-coded projection of the image was produced and compared to the 
reference spectra for each of the fluorophores. The spectra could then be separated by an 
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algorithm called linear unmixing. The resulting image produced a multichannel image 
displaying the fluorescence from each fluorophore separately.  
 
 
 
Figure 5: Schematic of emission fingerprinting procedure (Zeiss
[59]
). Samples 
are imaged individually as providing a reference emission spectrum. When the 
sample is imaged in the presence of all fluorophores, unmixing can be applied. 
Linear unmixing records the spectral profiles at each individual pixel and can 
therefore assign colours by consulting the reference spectra, in regions that would 
normally appear mixed.  
 
 
 
Emission spectra of the imaging controls used can be seen in figure 6.  
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Figure 6: Reference emission spectra from the individual fluorophores used 
in emission fingerprinting. Spheroids were fixed in the presence of one 
fluorophore. A region of interest with the brightest fluorescence was selected and 
an emission spectrum was generated. These spectra were recorded in a spectral 
database for use in emission fingerprinting to separate the spectral overlap of the 
GFP and YFP fluorophores.   
 
 
 
3.5 Western Blotting 
 
3.5.1 Protein Extraction 
 
To determine whether each cell line was representative of a glioma subtype, Western blotting 
was performed on protein extracted from each cell line. DMEM was removed and the cells 
washed three times with 1x PBS. 200 µl of radioimmunoprecipitation assay (RIPA) buffer (50 
mM Tris/HCL pH 7.5, 150 mM NaCl, 0.1% SDS, 1 mM EDTA pH 8, 0.5% sodium 
deoxycholate and 1% Triton-X-100) with added protease inhibitor cocktail (Sigma, P8340) 
was used to lyse the cells. The cells were then scraped, harvested and kept on ice for 20 
minutes. Following this, the cells were centrifuged (13,000 rpm, 15 minutes, 4°C) and 
GFP YFP 
RFP Hoechst 
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supernatant was then carefully transferred to a new microcentrifuge tube. Protein 
concentration was determined using Novagen BCA protein assay kit (Calbiochem, 71285-3). 
Samples were then diluted in Laemmli buffer 2x concentrate (Sigma-Aldrich, S3401-1VL) to 
normalise protein concentration.  
 
3.5.2 SDS-PAGE, Protein Transfer and Antibody Incubation 
 
15 µg of protein from each cell line was resolved by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE). Proteins were then transferred at 100 V (1 hour) onto nitrocellulose membrane. 
 
Following transfer, non-specific antibody binding was blocked by washing the blot in 5% 
milk-PBS-T (1 hour, RT). Primary antibodies in 5% milk-PBS-T, were incubated overnight at 
4°C. Anti-NF1 (Abcam, ab30325), anti-EGFR (Santa-Cruz, SC-03) and anti-IDH1 R132H 
(Dianova, DIA H09) were used at a 1:500 dilution. Anti-actin (Sigma, A4700) was used as a 
loading control (1:2000). Following primary antibody incubation, blots were washed with 
PBS-T three times and then probed with horseradish peroxidase-conjugated secondary 
antibody (Cell Signalling, anti-mouse IgG HRP-linked, #7076 or anti-rabbit IgG HRP-linked, 
#7074) at a 1:3000 dilution in PBS-T (1 hour, RT). Blots were then washed with PBS-T and 
developed using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare 
Life Sciences, RPN2232).  
 
3.6 Temozolomide Sensitivity Assays 
3.6.1 Adherent Monolayer Sensitivity Assay 
For monolayer TMZ sensitivity assays, the U373-RFP cell line was seeded at a density of 
1x10
4
 while the U343-YFP and U87-IDH1-Mutant-GFP were seeded at a density of 3x10
4
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into each well of a 12 well plate. Varying densities were used to account for the U373-RFP 
line growing at a significantly higher rate (previous observations).  
 
Two separate 12-well plates were prepared, one for TMZ treatment and one for a dimethyl 
sulfoxide (DMSO) control. A DMSO control was required since TMZ is diluted in DMSO 
and therefore the degree of cell death observed solely in the presence of DMSO needs to be 
accounted for. The 12-well plates were incubated at 37˚C overnight. Following incubation, 
the medium was removed and cells were treated with either DMSO or TMZ. 1 ml of 0.3, 0.5 
and 1 mM of TMZ in DMEM was added in triplicate. 0 mM TMZ was used as a control. On 
the other 12-well plate, 1 ml of 0.3, 0.5 and 1% DMSO, alongside a 0% DMSO control was 
added in triplicate. The cells were then incubated (37°C) for 72 hours. After 72 hours, 20% 
ice-cold triochloroacetic acid (TCA; Sigma-Aldrich, T0699) was added to each well to 
terminate the treatment. Plates were then incubated for 30 minutes at 4°C. The TCA was 
removed and the wells washed carefully three times with sterile distilled water (SDW). The 
plates were then left to dry for 2-3 hours. When dry, 0.4% Sulforhodamine B (SRB) in 1% 
acetic acid was added to each well and incubated (10 minutes, RT). Following incubation, the 
SRB solution was removed and plates washed 4-5 times with 1% acetic acid. Plates were left 
to dry overnight at RT. The following day, SRB stained wells were dissolved using 50 mM 
Tris/HCL pH8.8 and 100 µl of each well was transferred to a 96-well plate. The absorbance 
was then recorded at 495 nm on a microplate reader and cell viability calculated for each cell 
line.  
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3.6.2 Polyclonal TMZ Sensitivity 
Polyclonal spheroids were created as described in section 3.2.2, and left to form on stationary 
agarose plates for 3 days. Following spheroid formation, spheroids were retained on agarose 
plates and treated with either 1% DMSO (control) or 1 mM TMZ. Spheroids were incubated 
for 72 hours at 37˚C, 5% CO2. Spheroids were then harvested and subject to ICC (section 
3.3). Confocal microscopy was used to visualize the morphological changes (section 3.4).  
 
3.7 Analysis of Spheroid Morphology 
To calculate total spheroid and spheroid core volume, the diameter was calculated for each 
spheroid from confocal microscopy images using ImageJ (NIH). For each spheroid two 
perpendicular diameters were recorded and a mean diameter calculated. This was repeated to 
calculate the necrotic core volume. The volume of the spheroid and necrotic core were then 
calculated using the equation
[26, 60, 61]
: 
        
 
 
     
 
To calculate the spheroid wall thickness, spheroid images were divided into four and a 
measurement was taken from the outer edge to the necrotic core in each of the quarters. A 
mean width for each spheroid was then calculated using each of the quarters of the spheroid. 
Each image was calibrated to the scale bar.  
 
3.8 Statistical Analyses 
All statistical tests were performed using GraphPad Prism v6 for Macintosh (GraphPad 
Software, La Jolla California USA). Unpaired T-tests with unequal standard deviation (SD; 
Welch’s correction) were performed.  
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4. RESULTS 
 
4.1 Spheroid Optimisation 
In order that a suitable in vitro model of GBM might be obtained, it was essential that the 
spheroid culture method was optimised. Initially, spheroids were cultured in spinner flasks for 
7 days before extraction for confocal microscopy. Spheroids cultured using this method grew 
well however, when examined, were small in size and appeared non-viable. To overcome this, 
the liquid-overlay culture method was considered which produced, a high yield of viable 
spheroids after an incubation period of 2 days and therefore was adopted for subsequent 
experiments.  
 
Images produced from cultures stained with PIMO, designed to identify regions of hypoxia, 
demonstrated a faint signal and high background fluorescence. This was an issue as it 
prevented hypoxic regions from being clearly identifiable, thereby hindering analysis. To 
overcome this, the dilution of primary antibody was increased and the fixative used during 
ICC was changed from Acetone/Methanol to 10% formalin, which allows better sample 
preservation
[58]
. Although these changes produced clearer confocal images, PIMO still did not 
produce adequate staining and so HIF-1 was used as a marker for hypoxia, which produced 
clearer images. The confocal imaging also required optimisation, as previously described, and 
the permeabilisation time with Triton-X-100 was increased from 5 to 20 minutes to increase 
Hoechst 33342 dispersion.  
 
4.2 Western Blotting to Confirm GBM Subtype Representation  
Western blotting was used to confirm that the cell lines used had protein expression 
representative of the GBM subgroups, (table 2). Representative blots (figure 7) showed the 
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U343-YFP line expressed high levels of EGFR compared to the other cell lines. NF1 protein 
showed differential expression in the U373-RFP line in three experiments and would need to 
be repeated to confirm that this protein has been mutated. A R132H IDH1 mutation was 
detected in the U87-IDH1 mutant cell line but not the others, confirming that this cell line is 
characteristic of the Proneural subtype.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Western blots to confirm cell lines are representative of GBM 
subtypes. Protein was harvested from each cell line (three individual culture 
passages for U87 IDH1-WT-GFP, U87 IDH1-Mutant-GFP and U373-RFP, 2 
individual passages for U343-YFP). 15 µg of protein was separated by SDS-
PAGE gel electrophoresis. Subsequent blots were probed for NF1 (319 kDa), 
EGFR (170 kDa) and IDH1 Mutant (R132H; 47 kDa). Actin (42 kDa) was used as 
a loading control. It is apparent that NF1 loss was not seen in the U373-RFP cell 
line, however a lower level of expression was observed in an additional 
experiment. EGFR expression was high in the U343-YFP cell line, indicating that 
this cell line is representative of the Classical GBM subtype. An antibody against 
the mutant form of IDH1 confirmed that the U87 IDH1-Mutant-GFP cells express 
the IDH1 mutant enzyme.  
 
U87 
IDH1-
WT-
GFP 
U87 
IDH1-
MT-
GFP 
U343
-YFP 
U373
-RFP 
IDH1 R132H 
Actin 
Actin 
Actin 
NF1 
EGFR 
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4.3 Differential Morphology of Glioma Cell Lines  
Brightfield microscopy was used to examine growth of the glioma cells as adherent 
monolayers and multicellular spheroids. As seen in figure 8, the U87 IDH1-WT-GFP cell line 
is different to the U87 IDH1-Mutant in both monolayers and spheroids. The U87 IDH1-
Mutant-GFP cells typically displayed a spindle-like morphology and were slower growing. 
The U343-YFP cell line as adherent monolayers exhibited the slowest growth and when 
cultured in suspension, formed smaller, compact spherical spheroids. Conversely, the U373-
RFP cells exhibited very quick growth as monolayers and exhibited a punctate spheroid 
structure with individual cells visible on the spheroid periphery.   
 
 
Figure 8:  Morphology of glioma cell lines as adherent monolayers and 
multicellular spheroids. Distinctive morphology is exhibited in each cell line as 
adherent monolayers but also as multicellular spheroids. Magnification 20x.  
 
 
4.4 Monoclonal Spheroid Morphology  
Confocal microscopy was used to examine monoclonal spheroid morphology (figure 9).  
U87 IDH1-WT-GFP U87 IDH1-MT-GFP U343-YFP U373-RFP 
2D 
3D 
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Figure 9: Monoclonal spheroid morphology. Hoechst stain indicates the 
presence of DNA. It can be seen that there is a central core devoid of staining in 
the spheroids, indicating cell necrosis. PIMO staining indicates a region of 
hypoxic cells surrounding the necrotic core (i) U87 IDH1-WT-GFP monoclonal 
spheroid. A small layer of proliferating cells can be seen on the outer edge of the 
spheroid, with a large necrotic core. (ii) Monoclonal spheroid of the U87 IDH1-
Mutant-GFP cells. The spheroid has a high cell density and has a smaller 
necrotic core compared to the U87 IDH1-WT-GFP spheroid. A hypoxic rim is 
seen to surround the spheroid to the outer spheroid periphery. (iii) Representative 
image of U343-YFP monoclonal spheroids. It is apparent that the necrotic core 
is surrounded by a wall of high cell density. PIMO staining indicates that these 
cells are very hypoxic.  No evidence for the existence of a layer of non-hypoxic 
cells was visible in the outer periphery. (iv) Representative image of the U373-
U87-IDH1-WT-GFP U87-IDH1-MT-GFP 
U343-YFP U373-RFP 
(i) (ii) 
(iii) (iv) 
Hoechst Hoechst 
Hoechst Hoechst 
GFP GFP 
RFP YFP 
Merged Merged 
Merged Merged PIMO PIMO 
PIMO PIMO 
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RFP monoclonal spheroids. These spheroids had the smallest volume with a 
densely packed outer layer of cells and smaller necrotic core. As seen in the U87 
IDH1- Mutant-GFP and U343-YFP spheroids, the cells are hypoxic to the outer 
spheroid edge. Scale bar represents 50µm.  
 
 
U87 IDH1-WT-GFP cells formed spheroids with a large volume and a distinctively large 
necrotic core (figure 9(i)). Cells appeared to be loosely packed together, with a thin outer 
layer of proliferating cells. A hypoxic rim was seen below the spheroid periphery, detected by 
PIMO staining. The U87 IDH1-Mutant-GFPs (figure 9(ii)) however demonstrated a denser, 
tightly packed spheroid, with a smaller necrotic core. The hypoxic region was observed to be 
towards the outer edge of the spheroid, compared to the IDH1-WT, indicating that a greater 
volume of spheroid was more hypoxic. However more replicates are needed to confirm these 
observations. The U343-YFP cell line (figure 9(iii)), were considerably smaller with a tightly 
packed outer layer of proliferating/hypoxic cells and a smaller necrotic core. The hypoxic 
region was very pronounced around the outer edge of the spheroid indicating these spheroids 
were very hypoxic. U373-RFP spheroids (figure 9(iv)), demonstrated similar morphological 
characteristics to U343-YFP spheroids. 
 
4.5 Polyclonal Spheroid Morphology and Growth Characteristics  
After 3 days growth, spheroids were imaged using brightfield microscopy to observe their 
morphology (figure 10A). 
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Figure 10: Polyclonal spheroid morphology. Polyclonal spheroids were 
generated by mixing 1 x 10
6
 cells from each of the glioma cell lines. (A) 
Representative images of polyclonal spheroids after 3 days growth on stationary 
agarose plates. The spheroids formed dense cores, with clusters of cells around the 
outside of the spheroid. (B) Representative images of polyclonal spheroid growth 
over 3 days. Initially, the cells formed small cellular aggregates, which by day 2 
formed a much larger, more defined solid spheroid. By the day 3, the spheroids 
had more cells situated around the outer edge and also were prone to aggregation. 
Spheroids were used 3 days after seeding because the spheroids started to embed 
themselves into the agarose after this time. Magnification 20x. 
 
 
There is a clear difference in the polyclonal spheroid morphology (figure 10) compared to the 
monoclonal spheroids (figure 8). Polyclonal spheroids were formed of a solid core of cells, 
surrounded by smaller, punctate clumps of cells located on the periphery. Figure 10B shows 
this structural formation over the growth period of 3 days.  
 
 
 
A 
B DAY 1 DAY 2 DAY 3 
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4.6 Subtype Interactions Within Polyclonal Spheroids 
Confocal microscopy allowed for the different subtypes interactions to be identified. Due to 
the high spectral overlap of GFP and YFP fluorophores, the different subtypes could not be 
resolved (figure 11).  
 
 
 
Figure 11: Polyclonal spheroid before separation of GFP/YFP fluorophores. 
It is apparent that the fluorescence from the GFP and YFP fluorophores could not 
be distinguished from one another, producing one image with fluorescence from 
both fluorophores, as opposed to two separate images as expected. Therefore the 
clonal interactions could not be determined. Scale bar represents 50µm. 
 
 
Figure 12 shows representative images of the polyclonal spheroids following separation of the 
fluorophores. These spheroids were very cell dense, with little or no necrotic core present. 
The U373-RFP and U87 IDH1-Mutant-GFP cells appear to localise together whereas there is 
a distinct location of the U343-YFP cells. In every image analysed (N=18), from 3 
independent experiments, the U343-YFP cells were situated on the outer spheroid, indicating 
a possible important function.  
Hoechst GFP/YFP RFP Merged 
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Figure 12: Confocal images showing subtype interactions in polyclonal 
spheroids. Representative images of polyclonal spheroids showing the 
interactions and locations of the cell lines representative of the four GBM 
subtypes. U373-RFP and U87 IDH1-Mutant-GFP were observed to co-localise. 
The U343-YFP cells however demonstrated a clear and distinctive location 
around the outer periphery of the spheroid suggesting a specialised function of 
this representative GBM subtype. The spheroids also lacked a distinctive necrotic 
core, as shown by Hoechst dye penetrating to the spheroid centre. 3 independent 
experiments were performed, 18 images. Scale bar represents 50 µm.  
 
 
Staining for hypoxic regions could not be processed in the same confocal channel, thus the 
polyclonal spheroids, from the same experiments as above, were individually imaged for 
Hoechst and hypoxia staining (figure 13). 
 
 
U373-RFP U87 IDH1-MT-GFP Hoechst U343-YFP Merged 
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Figure 13: Polyclonal spheroids are mainly hypoxic with little necrosis 
present. Representative images showing polyclonal spheroids stained with 
Hoechst 33342 and for hypoxic regions with HIF-1α. These spheroids were very 
dense, with smaller necrotic cores as the Hoechst dye was observed to penetrate to 
the centre of the spheroids. Hypoxia staining was very strong throughout the 
spheroid indicating that the polyclonal spheroids were almost entirely hypoxic 
compared to the monoclonal spheroids seen in figure 9, where only a layer of 
hypoxic cells were seen. These images were used for quantitative analysis of the 
polyclonal morphology. 3 independent experiments were performed, 18 images. 
Scale bar represents 50µm.  
 
 
4.7 Analysis of Monoclonal and Polyclonal Morphological Characteristics 
Spheroid morphology was quantitatively analysed (figure 14). Spheroid diameter of U87 
IDH1-WT-GFP and-Mutant-GFP spheroids was larger than both the U343-YFP and U373-
RFP spheroids, with the U373-RFP being the smallest polyclonal spheroid, however was not 
statistically significant. The U87 IDH1-Mutant-GFP spheroids had the largest spheroid 
volume, tightly packed and exhibited a high cell density, (figure 9(ii)). U373-RFP produced 
the smallest spheroid, which were significantly (p=0.0038) smaller than the polyclonal 
Hoechst HIF-1α Merged 
  
 
32 
spheroids. The volume of the necrotic core was also measured and the U87 IDH1-WT-GFP 
appeared to demonstrate the largest core volume. The U87 IDH1-Mutant-GFP spheroids 
however had considerably smaller necrotic core volume compared with other spheroids, 
despite having the largest overall volume. However, these observations were not statistically 
significant as more replicates are needed. The U373-RFP exhibited the smallest necrotic core, 
being the smallest spheroid overall. The polyclonal spheroids also demonstrated typically 
small necrotic cores (figure 12).  
 
The necrotic core to spheroid volume ratio was calculated demonstrating that the U87 IDH1-
WT-GFP spheroids had the largest necrotic core, with 27% of the spheroid being necrotic. 
The other spheroids however had a much smaller degree of necrosis, with polyclonal 
spheroids having on average 8.5±1.7% necrosis. U87 IDH1-WT-GFP spheroids had the 
thinnest layer of proliferating and hypoxic cells whereas, conversely, the U87 IDH1-Mutant-
GFP had the thickest cell wall amongst the monoclonal spheroids. The polyclonal spheroids 
had the thickest cell wall that was particularly cell dense and also highly hypoxic.   
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Figure 14: Quantitative analysis of monoclonal and polyclonal spheroid 
characteristics. (i) Mean spheroid diameter. U87 IDH1-WT-GFP and –Mutant-
GFP were seen to produce the largest spheroids of the 4 monoclonal subgroups 
(i) (ii) 
(iii) (iv) 
(v) 
U
87
 ID
H
1-
W
T-
G
FP
U
87
 ID
H
1-
M
ut
an
t-
G
FP
U
34
3-
YF
P
U
37
3-
R
FP
P
ol
yc
lo
na
l
0
50
100
150
200
250
300
A
v
e
ra
g
e
 S
p
h
e
ro
id
 D
ia
m
e
te
r 
(µ
m
)
**
U
87
 ID
H
1-
W
T-
G
FP
U
87
 ID
H
1-
M
ut
an
t-
G
FP
U
34
3-
YF
P
U
37
3-
R
FP
P
ol
yc
lo
na
l
0
2×106
4×106
6×106
8×106
1×107
A
v
e
ra
g
e
 S
p
h
e
ro
id
 V
o
lu
m
e
 (
µ
m
3
)
**
U
87
 ID
H
1-
W
T-
G
FP
U
87
 ID
H
1-
M
ut
an
t-
G
FP
U
34
3-
YF
P
U
37
3-
R
FP
P
ol
yc
lo
na
l
0.0
5.0×105
1.0×106
1.5×106
2.0×106
2.5×106
A
v
e
ra
g
e
 C
o
re
 V
o
lu
m
e
(µ
m
3
)
U
87
 ID
H
1-
W
T-
G
FP
U
87
 ID
H
1-
M
ut
an
t-
G
FP
U
34
3-
YF
P
U
37
3-
R
FP
P
ol
yc
lo
na
l
0
5
10
15
20
25
30
C
o
re
 V
o
lu
m
e
 t
o
 S
p
h
e
ro
id
 V
o
lu
m
e
 
R
a
ti
o
 (
%
) 
  
 
34 
(U87-IDH1-WT-GFP: 241.6 µm, 1 image; U87 IDH1-Mutant-GFP: 262.1 µm, 1 
image; U343-YFP: 182.4 ± 27.66 µm, 5 images; U373-RFP: 161.6 ± 9.61 µm, 7 
images) and Polyclonals (203.5 ± 6.88 µm, 18 images). However the difference 
between U373-RFP and the polyclonal spheroids was the only one that was 
statistically significant (unpaired T-test, P value= 0.0038).  (ii) Mean spheroid 
volume. U87 IDH1-WT-GFP and U87 IDH1-Mutant-GFP expressed the largest 
volume of the spheroids (U87-IDH1-WT-GFP: 7.39 x 10
6 
µm
3
, 1 image; U87 
IDH1-Mutant-GFP: 9.43 x 10
6 
µm
3
, 1 image; U343-YFP: 4.09 ± 1.62 x 10
6 
µm
3
, 5 
images; U373-RFP: 2.36 ± 0.47 x 10
6 
µm
3
, 7 images; Polyclonals: 4.67 ± 0.46 x 
10
6 
µm
3
, 18 images) though, as shown with the mean spheroid diameters, only the 
difference observed between U373-RFP and the polyclonals was significant 
(unpaired T-test, P value= 0.0025). (iii) Mean necrotic core volume. U87 IDH1-
WT-GFP spheroids exhibited a large area of necrosis compared to the U373-RFP 
and polyclonal spheroids, which had smaller cores. (U87-IDH1-WT-GFP: 1.96 x 
10
6
µm
3
, 1 image; U87 IDH1-Mutant-GFP: 0.86 x 10
6
µm
3
, 1 image; U343-YFP: 
0.70 ± 0.40 x 10
6
µm
3
, 5 images; U373-RFP: 0.26 ± 0.08 x 10
6 
µm
3
, 7 images; 
Polyclonals: 0.44 ± 0.10 x 10
6
µm
3
, 18 images). (iv) Necrotic core to total 
spheroid volume ratio. U87 IDH1-WT-GFP spheroids had the largest ratio 
compared to the other spheroids (U87 IDH1-WT-GFP: 26.5 %, 1 image; U87 
IDH1-Mutant-GFP: 9.2%, 1 image; U343-YFP: 13.1 ± 2.9%, 5 images; U373-
RFP: 9.8 ± 1.8%, 7 images; Polyclonals: 8.5 ± 1.7%, 18 images). (v) Spheroid 
wall thickness. The spheroid wall thickness was measured from the spheroid 
periphery to the necrotic core. Polyclonal spheroids had the thickest cell wall 
(66.9 ± 4.40 µm, 18 images), which was statistically significant compared with 
U343-YFP (unpaired T-test, P value= 0.002) and U373-RFP (unpaired T-test, P 
value= 0.0001) spheroids whereas the U87 IDH1-WT-GFP spheroid had a 
comparatively thinner cell wall (29.9 µm, 1 image), despite having a greater 
overall volume. Other monoclonal spheroids had cell wall thicknesses that fell 
between this range (U87 IDH1-Mutant-GFP: 61.0 µm, 1 image; U343-YFP: 44.8 
± 3.93 µm, 5 images; U373-RFP: 42.0 ± 3.12 µm, 7 images) though none of these 
differences were found to be significantly different. Bars show the mean values 
for each measurement. Error bars represent  ±SEM. 
 
 
4.8 Temozolomide Sensitivity Assays of Monoclonal Adherent Monolayers  
TMZ sensitivity of each cell line was investigated when grown as adherent monolayers 
(figure 15). It is clear from this data that the most sensitive was U373-RFPs, which showed an 
average 33% cell death with increasing concentrations of TMZ. The U87 IDH1-Mutant-GFP 
and U343-YFP cell lines however were less sensitive to TMZ treatments with only 22% cell 
death after treatment with1 mM TMZ.  
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Figure 15: Glioma cell lines show differential sensitivity to TMZ treatment as 
adherent monolayers. Each cell line was subject to TMZ treatment for 72 hours 
after which the cell viability was measured using a SRB assay. U373-RFP cells 
were more sensitive to 0.3, 0.5 and 1mM TMZ treatments (0.3 mM- 0.67 ± 0.03, 
0.5 mM- 0.66 ± 0.04, 1 mM- 0.68 ± 0.06) compared with both the U87 IDH1-
Mutant-GFP (0.3 mM- 0.83 ± 0.14, 0.5 mM- 0.89 ± 0.10, 1 mM- 0.79 ± 0.19) and 
U343-YFP (0.3 mM- 0.88 ± 0.13, 0.5 mM- 0.86 ± 0.08, 1 mM- 0.78 ± 0.08) cell 
lines. Despite there being a strong distinction between the mean cell viability of 
these spheroids, they were not found to be significantly different). 4 independent 
experiments were conducted for U373-RFP and U343-YFP cell lines and 3 
independent experiments for U87 IDH1-Mutant-GFP cells. Error bars represent 
±SEM.  
 
 
4.9 Polyclonal Spheroid Growth and Morphology Following TMZ Treatment  
Polyclonal spheroids treated with 1 mM TMZ were examined using brightfield microscopy to 
investigate whether there was any noticeable difference in spheroid morphology (figure 16). 
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Figure 16:  Morphology of polyclonal spheroids following TMZ treatment. 
Polyclonal spheroids were seeded and left to grow for 3 days on stationary 
agarose plates so that spheroids could form, after which they were treated with 1 
mM TMZ (iii and iv) or DMSO (control; i and ii) for 72 hours. There was no 
apparent difference in spheroid morphology between these treatments as complete 
spheroids were retained in both conditions. It should be noted however, that upon 
addition of TMZ, more single cells and small cellular aggregates were present 
compared to the control condition, indicating that there may have been more 
dissolution of the spheroids upon TMZ treatment. 
 
 
Following immunocytochemistry, polyclonal spheroids with and without TMZ treatment 
were imaged using confocal microscopy (figure 17). In the control condition, the U343-YFP 
cell line was situated on the far edge of the spheroid, as seen with the polyclonals (figure 12). 
It should be noted that there were very few U343-YFP cells incorporated into the spheroid. 
The quantity and location of the U343-YFP cells was observed in every control image taken, 
from 2 experiments. A defined necrotic core was seen within these spheroids, which were 
surrounded by a tightly packed layer of U373-RFP and U87 IDH1-Mutant-GFP cells. Upon 
TMZ treatment however the necrotic core was observed to be considerably larger and the 
Control 
TMZ 
(i) (ii) 
(iii) (iv) 
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layer of proliferating cells on the edge of the spheroid were reduced. TMZ treated spheroids 
also demonstrated the proliferation and dramatic relocation of the U343-YFP cell line. In all 
images, U343-YFP cells appeared to have increased and relocated to fill the central core of 
the spheroid. This is remarkably different to the control and polyclonal spheroids.   
 
 
 
Figure 17: TMZ treatment of polyclonal spheroids causes a dramatic 
proliferation and relocation of the U343-YFP cells.  In the control condition, 
the U373-RFP and U87 IDH1-Mutant-GFP localised in similar regions of the 
spheroid. The U343-YFP had a similar location as seen previously (figure 12), 
situated around the outside of the spheroid. There was also a reduced amount of 
these cells present in these spheroids. A large necrotic core was present in these 
spheroids, which had not been observed in previous polyclonal images, 
suggesting that this may be due to the presence of DMSO, or the longer period of 
growth on the agarose plates. Upon addition of 1 mM TMZ (72 hours incubation) 
however, there was a noticeable relocation and proliferation of the U343-YFP 
cells into the central core of the spheroids suggesting the possibility of a 
specialised function to these cells. The spheroid walls appear to be thinner than 
seen in the control with a larger necrotic core, although it was filled with U343-
YFP cells. Scale bar represents 50 µm.  
 
 
4.10 Analysis of Polyclonal Spheroid Morphology Following TMZ Treatment 
Quantitative analysis of spheroid morphology following TMZ treatment was performed 
(figure 18). After TMZ treatment, the mean diameter of the polyclonal spheroids increased in 
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size compared to the control, however was not significantly different. Spheroid volume 
showed that after TMZ treatment the volume increased, however was not significant. Analysis 
of the necrotic core volume again showed that the core was significantly larger upon TMZ 
treatment, although the core was filled with U343-YFP cells, which was not apparent in the 
control spheroids. Analysis of the percentage of core to the total volume showed that TMZ 
treated spheroids to have significantly (p=0.003) larger core than control spheroids, being 
around 50% of the total spheroid volume. Finally, cell wall diameter was measured which 
showed that the control spheroids had a thicker layer of cells surrounding the necrotic core 
compared to the TMZ treated spheroids, however results were non-significant. In the confocal 
images (figure 17) it can be seen that there is a reduction in the presence of the U373-RFP 
cells on the outside of the spheroid, which could potentially be linked to its sensitivity to 
TMZ treatment showed in figure 15.  
 
 
(i) (ii) (iii) 
(iv) (v) 
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Figure 18: Quantitative analysis of polyclonal spheroid morphology after 
TMZ treatment. (i) Mean spheroid diameter. The mean spheroid diameter 
increased upon TMZ treatment however was not significant compared to the 
control condition (Control: 172 ± 10.3 µm, 7 images; TMZ: 203.2 ± 14.7 µm, 8 
images). (ii) Mean spheroid volume. The average spheroid volume was 
determined and demonstrated an apparent increase with the addition of TMZ 
(Control: 2.83 ± 0.48 x 10
6 
µm
3
, 7 images; TMZ: 4.87 ± 0.94 x10
6 
µm
3
, 8 
images). (iii) Mean necrotic core volume. A significant increase (unpaired T-
Test, P value=0.0285) was observed in the necrotic core volume with TMZ 
compared to the control (Control: 0.97 ± 0.21 x 10
6 
µm
3
, 7 images; TMZ: 2.51 ± 
0.55 x 10
6 
µm
3
, 8 images). (iv) Necrotic core to total spheroid volume ratio. 
The mean core to volume ratio demonstrated that there is significant increase 
(unpaired T-test, P value=0.003) in the percentage of necrosis of the overall 
spheroid with TMZ treatment (Control: 32.4 ± 2.5%, 7 images; TMZ: 49.8 ± 
3.9%, 8 images). (v) Spheroid wall thickness. The mean wall thickness of the 
spheroids was seen to decrease upon TMZ treatment, however this was not 
significant compared to the control condition (Control: 25.7 ± 1.2 µm, 7 images; 
TMZ: 21.1 ± 1.9 µm, 8 images). 2 independent experiments were conducted. Bars 
show the mean values for each measurement. Error bars represent ±SEM.  
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5. DISCUSSION 
 
5.1 Representation of GBM Subtypes Through Cell Lines 
 
Understanding the polyclonal nature and heterogeneity of GBM is imperative for determining 
effective treatments tailored to patients. To investigate clonal interactions, a representative in 
vitro model which expresses the different GBM subtypes is required as current models do not 
accurately represent in vivo gliomas. Three cell lines, U87 IDH1-Mutant-GFP, U343-YFP and 
U373-RFP, were chosen in this project to best represent GBM subtypes in a polyclonal 
spheroid model.  
 
Western blotting (figure 7) confirmed that the U343-YFP cell line highly expressed EGFR 
protein, which is characteristic of the Classical GBM subtype (table 1). It has previously been 
reported that, when culturing glioma cells, Chromosome 7p amplification, containing the 
EGFR gene locus, can be lost within short-term culture
[55, 56].
 However, during this 
experiment high EGFR expression was conserved despite continuous culture. Therefore, the 
U343-YFP line preserved a typical characteristic best representative of the Classical GBM 
subtype during this investigation. 
 
The U87 IDH1-Mutant-GFP cell line was confirmed to express the mutated IDH1 enzyme 
(figure 7). Like EGFR, it has been shown that IDH1 mutations cannot be sustained in culture 
conditions
[56]
. Therefore, the U87 IDH1-Mutant-GFP cell line had been engineered
[57]
 to 
overexpress the IDH1 mutant and these results confirm that the introduced mutation was 
sustained through cell passages. This cell line is therefore representative of the Proneural 
subtype.  
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NF1 expression was shown to be differentially expressed in the U373-RFP cell line across 
three experiments performed within this project and would therefore require further 
investigation to confirm that this cell line is representative of the Mesenchymal subtype, as 
believed. This cell line should be sequenced to ensure the NF1 deletion is present and 
Western blotting performed with more harvested protein, potentially with a different NF1 
antibody to test antibody specificity. In addition, other proteins characteristic of the 
Mesenchymal subtype, for example the presence of markers such as CH13L1 and cadherin-
11
[62]
, could be investigated. It should not however be assumed that these cell lines are exact 
representations of each GBM subtype as they do not exhibit all mutations and amplifications 
present in in vivo tumours. Nevertheless, these cell lines are considered to provide a good 
representation of glioma subtypes to develop a suitable in vitro model to study GBM 
heterogeneity.  
 
5.2 Monoclonal Spheroid Morphology 
Tumour growth is typically defined by an exponential growth phase of proliferating cells, 
followed by a decline in cell proliferation generally associated with the increase of quiescent, 
non-proliferating cells within the spheroid outer region and necrotic cells within the spheroid 
core
[50]
. This stratified arrangement is dependent on factors including cell type, density and 
nutrient consumption rates
[50]
. Figure 9 shows these differences observed in monoclonal 
spheroid morphology. The U87 IDH1-WT-GFP cells quickly formed large spheroids with an 
extensive area of necrosis, a rim of hypoxic and potentially quiescent cells and a single layer 
of proliferating cells. These observations suggest that these spheroids were able to quickly 
exhaust nutrients and oxygen, resulting in a large proportion of cell death. Comparing the U87 
IDH1-WT-GFP to the IDH1-Mutant-GFP spheroids, there was a distinct difference in 
morphology. In the presence of mutant IDH1, the spheroids were denser, with the cells tightly 
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packed together forming a thicker wall of proliferating/quiescent cells surrounding a smaller 
necrotic core. Spheroids were also hypoxic to the outer edge, which was not seen in the U87 
IDH1-WT-GFP spheroids. These observations suggest that the presence of mutant IDH1 
permitted better survival of the spheroid due to the smaller proportion of necrotic cells 
present. Research has documented that the presence of mutant IDH1 enzyme is required for 
IDH1 mutated tumour cell growth
[63]
 and an inhibitor of R132H-mutated IDH1 delayed cell 
growth
[64]
, suggesting that mutated IDH1 promotes growth, sustaining tumour viability. 
 
Compared to the U87 IDH1-WT-GFP or –Mutant-GFP monoclonal spheroids, the U343-YFP 
and U373-RFP cells formed much smaller and tightly packed spheroids, with a considerably 
thicker cell wall and smaller necrotic core, showing a distinctive difference in morphology 
between these cells lines. The presence of a smaller necrotic core also suggests that these 
spheroids are better at surviving under reduced oxygen and nutrient conditions, which may 
influence the polyclonal spheroid survival. 
 
Analysis of the U373-RFP cell line (figure 9) demonstrated that RFP fluorescence was 
particularly irregular. Despite being cultured in medium containing puromycin, which 
allowed for selection of RFP expressing cells, the overall fluorescent labelling was not 
uniform. To improve this, U373-RFP cells could be re-sorted using FACS to select the 
highest RFP expressing cells. If the fluorescence of this tag could not be optimised, different 
fluorescent tags could be used such as improved variants of RFP, DsRed or mCherry 
(emission maximum values of 592nm and 610nm respectively), which would not interfere 
with emission spectra of the other fluorescent tags and should facilitate imaging.  
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All cell lines were seen to not emit Hoechst fluorescence in the central region of the 
spheroids, indicating necrotic and dead cells (figure 9). However, YFP, and in some regions 
RFP, were still expressed in the central spheroid core indicating potentially viable cells. This 
suggests that perhaps Hoechst was not able to fully penetrate and bind to DNA in the spheroid 
centre due to spheroid thickness. Weiswald et al., 2010
[65]
 investigated the optimal 
immunocytochemistry parameters for intact spheroids. They found that simultaneously fixing 
and permeabilising the spheroids in a solution of paraformaldehyde and Triton-X-100, 
followed by dehydration in methanol allowed complete dye penetration whilst retaining 
spheroid structure
[65]
. A future improvement however, would be to combine fixation and 
permeabilisation steps and extend incubation time as described in Weiswald et al., 2010
[65]
. 
Nevertheless, when imaging polyclonal spheroids (figures 12 and 13) it is apparent that 
Hoechst is present in the spheroid centre. However, to ensure that Hoechst infiltration is not a 
problem when imaging the monoclonal spheroids, a different dye could be used in 
combination to check cell viability. NucRed® Dead 647 ReadyProbes® Reagent (Life 
Technologies) could be used after spheroid fixation, and would bind to nuclear DNA in cells 
with compromised cell membranes, hence staining for the presence of dead cells.  
 
5.3 Relationship of Subtypes Within Polyclonal Spheroids 
Confocal microscopy showed that there was a differential location of the subtypes within the 
polyclonal spheroid model. It is apparent (figure 12) that U373-RFP and U87 IDH1-Mutant-
GFP cells co-localise forming a tight, cell-dense spheroid body, with little to no necrosis. This 
shows that these cells are able to survive in oxygen and nutrient deprived environments and 
promote the overall spheroid survival. This is an example of mutualism where different 
subtypes are positively interacting to benefit the survival of other clones, therefore providing 
an evolutionary advantage of the tumour. The entire spheroid is seen to be very hypoxic, 
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noted by the presence of HIF-1α (figure 13) suggesting that these spheroids could potentially 
be using this as a mechanism of survival. Tumour hypoxia is present within solid tumours due 
to large amounts of oxygen being consumed during the tumours rapid proliferation. Within 
gliomas, the majority of tumour cells in grade IV GBM are known to be hypoxic
[66]
 compared 
to lower grades. Additionally, the presence of moderate to severe hypoxia has been correlated 
with a more aggressive tumour behaviour
[66]
 and increased resistance to radiation and 
chemotherapy
[67]
. To overcome the limited oxygen supply and reduce cell death, tumour cells 
are known to alter their metabolism to sustain proliferation. Hypoxia-inducible factors (HIFs), 
induced under hypoxic conditions, play a key role in this altered metabolism since they up-
regulate genes key for tumour survival, such as those involved in invasion, and also glycolytic 
genes, which manage survival upon reduction in oxygen availability
[68]
.  
 
HIF-1α has been shown to be located in areas adjacent to necrosis and also within invading 
tumour cells situated at the spheroid periphery
[67, 71]
. This is interesting because results (figure 
12) demonstrate the distinctive location of potentially very hypoxic U343-YFP cells on the 
invading edge. This clonal interaction and location is particularly important, as these cells are 
known to overexpress EGFR. Constant activation of the EGF receptor activates downstream 
cascades that promote tumourigenesis, anti-apoptosis, invasion and can lead to uncontrolled 
cell proliferation
[9]
. Studies, such as those conducted by Okada et al., 2003, showed that cells 
containing an EGFR-amplification were preferentially located in clusters on the outer, 
invading edge of the tumour compared to relatively small amounts located in the solid tumour 
core. The results of this investigation corroborate these findings as the EGFR expressing 
U343-YFP cells were observed on the outer spheroid edge (figure 12). This might suggest 
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that these cells have a specific role within the polyclonal spheroid, promoting infiltration of 
into surrounding tissue.  
 
This apparent co-operation between the subclones is particularly important when relating to 
GBM patients since differential treatment sensitivity has been shown
[19]
. Because these clones 
work together to benefit the survival of the tumour, further investigation is needed to 
determine a method of treatment that will dissolve these specific pro-survival interactions thus 
targeting the whole tumour and not individual subtypes. 
 
5.4 Issues Relating to Confocal Microscopy Issues and Analysis  
Problems were encountered whilst using confocal microscopy to investigate the clonal 
relationships. Fluorescence from GFP and YFP tagged cells could not be separated due to 
overlapping emission spectra. This problem was resolved using a computer algorithm to 
separate the fluorescence. Although this is a valid method, there could be debate as to whether 
the fluorophores have been entirely separated. Therefore, to confirm the cell locations within 
the spheroid model, untagged U343 cells could be incorporated instead. Cells would then be 
probed for EGFR, since they highly express the protein, and then detected using the DyLight-
649 secondary antibody, which emits fluorescence in the far-red region. Consequently, there 
would be no risk of spectral overlap, providing absolute conformation of subtype locations. 
For a more long-term solution, the cells would ideally be designed to express a more 
compatible range of fluorescent tags, though this would require further investigation. 
 
To quantitatively analyse monoclonal and polyclonal morphologies, total spheroid and 
necrotic core volumes were measured (section 3.8)
[60]
. However this method may not be the 
best to accurately calculate spheroid volume as these cell cultures are not perfect spheroids or 
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uniform in size. Therefore, an improved method may be to use computational programming 
and imaging software to calculate the area of spheroid slices and 3D reconstruction to 
calculate overall volume. 
 
5.5 Differential Sensitivity of Glioma Subtypes to Temozolomide Treatment 
Inter- and intra-tumoral heterogeneity is known to comprise treatment strategies since tumour 
cells often develop resistance mechanisms (section 1.2). Different glioma subtypes can 
exhibit a differing response to chemotherapy and radiotherapy
[19]
 however GBM patients are 
treated with the same aggressive course of treatment, regardless of subtype. Therefore, it is 
important that this varied response to treatment is investigated.  
 
Temozolomide sensitivity was investigated in each subtype grown as adherent monolayers. 
Figure 15 shows that the most sensitive of the three cell lines to 72-hour treatment of TMZ 
was U373-RFP (Mesenchymal subtype). U87 IDH1-Mutant-GFP and U343-YFP cells were 
more resistant to TMZ treatment, and only exhibited around 20% cell death with 1 mM TMZ. 
These cells are potentially more hypoxic, as seen with HIF-1α localisation (figures 9, 12 and 
13), and because the IDH1 mutation is thought to promote stabilised expression of HIF-1α. 
Studies have also shown that TMZ treatment can up-regulate many HIF-1α target genes[72],  
contributing to increased resistance by inducing cell cycle arrest of tumour cells and therefore 
providing protection against agents such as TMZ, that induce cellular apoptosis
[71].
 To 
confirm this hypothesis, TMZ sensitivity assays could be combined with either a small-
interfering RNA designed to target HIF-1α or a small molecule inhibitor such as Chetomin, 
which disrupts the HIF pathway, attenuating HIF expression
[73]
.
 
TMZ sensitivity in glioma 
cells has been shown to be increased upon inhibition of HIF-1α and shown to be a possible 
target in glioma treatment
[74]
.   
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Additionally, MGMT status of glioma cells lines should be determined to see if this is causing 
TMZ resistance, observed in the U87 IDH1-Mutant-GFP and U343-YFP cells (figure 15). 
According to Verhaak et al., 2010
[19]
 the Proneural subclass do not benefit from TMZ 
treatment compared to other subgroups. This is seen within the 2D sensitivity experiments 
(figure 15) in this project. Because TMZ treatment in patients is usually combined with a 
course of radiotherapy to provide the best survival outcome
[3]
, future experiments should also 
compare sensitivity with radiation, both alone and combined with TMZ.  
 
TMZ sensitivity of the polyclonal spheroids was examined using confocal microscopy. The 
data (figure 17) show that in the control condition U343-YFP cells are again situated on the 
invading edge of the spheroid and are small in number. A large necrotic core was present in 
these spheroids, which was not apparent in the untreated polyclonal cultures. This is 
potentially explained by cell death by DMSO addition or because spheroids were left for a 
further three days, after the initial two day growth phase, which may have allowed a steeper 
oxygen gradient to form across the spheroid.  
 
With TMZ treatment there was a pronounced relocation and proliferation of the U343-YFP 
cells (figure 17). The spheroid core also significantly increased in size, however U343-YFP 
cells were observed within this core. This suggests that these cells are part of a mechanism 
benefiting the overall survival of the spheroid model. EGFR amplifications, as previously 
discussed, induce cell proliferation and can influence tumour cell survival, invasiveness and 
most importantly, resistance to treatment
[75]
. Therefore the data from this project suggests that 
amplification in EGFR signalling provides an important mechanism of resistance to TMZ 
treatment. Further experiments are required to investigate whether it is EGFR signalling 
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which is responsible for this dramatic relocation and proliferation of U343-YFP cells. A 
selective EGFR inhibitor such as Erlotinib
[76]
 or Imantinib should be used to investigate 
whether inhibition of EGFR would inhibit the relocation of these cells. Additionally, the U87 
cell line could be engineered to overexpress EGFR to see if these cells could proliferate and 
migrate to the spheroid core upon TMZ treatment. Furthermore, there was no visible staining 
of DNA from U343-YFP cells in the spheroid centre (figure 17). To check the cell viability, a 
TUNEL assay or detection of Capase-3, which detects the presence of apoptotic cells, could 
be performed. Combined, these experiments would be able to confirm that EGFR is a key 
mediator in this interesting response to TMZ treatment. A further experiment of interest 
would be to use live-cell imaging to observe real-time alterations and migrations of the 
subclones upon treatment. This would give great indication as to when EGFR expressing cells 
relocate and how they proliferate to benefit the overall spheroid survival.  
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6. CONCLUSION 
 
The data presented in this investigation suggests that 3D cell culturing produces a more 
representative model of GBM compared with existing 2D models. Initial observations using 
this model suggest that different glioma subtypes exhibit distinct morphologies both in 
monoclonal and polyclonal communities. However, certain problems were encountered 
during analysis (sections 3.4.2 and 5.4), which require optimisation in order to improve the 
effectiveness of this model. Furthermore, an improved spheroid co-culture model could be 
developed by introducing microglial cells to provide a comparable tumour microenvironment 
for the spheroids. Moreover, GBM tumour spheroids could be created using tumour fragments 
obtained from patient resections, along with the creation of a microenvironment, would 
provide an even more representative in vitro model of GBM.   
 
Polyclonal TMZ studies showed a novel subtype interaction, where U343-YFP cells 
dramatically proliferated and relocated to the spheroid core, suggesting a mechanism of 
spheroid survival under adverse conditions. However. additional experiments are needed to 
this further investigate this observation.  Nevertheless, this work represents a significant 
improvement into how GBM is investigated in vitro and, with further development, will 
increase our understanding of glioma heterogeneity resulting in more effective therapy for 
GBM patients. 
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ABSTRACT 
 
Schizophrenia is a psychotic disorder affecting approximately 1% of the global population. 
Schizophrenia is a heterogeneous disease with a complex aetiology including neurotransmitter 
abnormalities, viral infection and genetic predisposition. More recently, research focus has 
shifted to investigate the role of the immune system in schizophrenia development. Studies 
report an elevation in pro-inflammatory cytokines, such as tumour necrosis factor-α (TNF-α), 
in patients with schizophrenia. However, there is a level of ambiguity within these studies as 
factors such as medication can significantly affect cytokine levels and have often not been 
controlled for in previous studies. This study aimed to resolve this uncertainty by 
investigating TNF-α release from monocytes obtained from medication-naïve patients, which 
had been demographically matched to healthy individuals. Results showed a small, but non-
significant increase in TNF-α release. Additionally, it has been shown that the nicotinic 
acetylcholine receptor (nAChR) is important in cytokine regulation and following activation, 
inhibits pro-inflammatory cytokine release. This study also investigated a nAChR activator, 
4BP-TQS in cytokine release and results showed a significant reduction in TNF-α production 
from THP-1 monocytes. Further investigation of nAChR agonists is desirable in 
schizophrenia research to provide an alternative anti-inflammatory treatment to relieve 
negative symptoms associated with increased inflammation. 
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1. INTRODUCTION 
 
1.1 Schizophrenia  
 
Schizophrenia is a serious psychotic disorder affecting approximately 1% of the global 
population
[1]
 and generally manifests as a psychotic episode in late adolescence or early 
adulthood
[1]
. Clinical schizophrenia is diagnosed following periodic occurrence of these 
psychotic episodes over a six-month period
[2]
. Symptoms of schizophrenia are characterized 
into 3 classes, positive, negative and cognitive
[3]
. Positive symptoms are generally only 
exhibited in schizophrenic patients and include delusions, extreme paranoia, disorganised 
thought and visual and auditory hallucinations; otherwise known as psychosis
[1]
. Negative 
symptoms, refer to mental processes normally observed in the healthy population but are 
absent in patients. These symptoms include social and emotional withdrawal, apathy, lack of 
motivation and anhedonia
[1]
. Cognitive symptoms include dissolution of neurological 
processes such as memory and attention. Collectively, the broad spectrum of these symptoms 
can severely impair everyday activities for patients such as employability
[4]
 and maintaining 
social relationships
[5]
 and therefore it is imperative that effective treatments are designed to 
target all classes of symptoms.  
 
There are many theories concerning schizophrenia aetiology and how early psychosis can 
progress to clinical schizophrenia. To date, the majority of schizophrenia research has focused 
on neurotransmitter abnormalities within the dopaminergic
[6, 7]
 and glutamatergic systems
[8]
, 
viral infection
[9, 10]
 and genetic influence
[11]
 on disease development. Historical research 
involving monozygotic twin and adoption studies have shown a strong genetic predisposition 
to schizophrenia as the risk of a relative of a schizophrenic individual developing the disorder 
is approximately 80%
[12]
. Although a large number of studies have identified genetic variants 
  2 
that increase the susceptibility of developing schizophrenia, such investigations only explained 
a small minority of cases
[11, 13]
. It therefore seems apparent that schizophrenia is a 
heterogeneous disease with a complex aetiology. More recently, research focus has diverted to 
the contribution of the immune system within disease development.  
 
1.2 Immune Dysregulation Theory of Schizophrenia Aetiology 
1.2.1 Inflammation and Role of Cytokines 
Inflammation is an immediate biological mechanism designed to protect and induce healing in 
response to harmful physiological stimuli, such as tissue damage, invasive pathogens and 
cellular stress
[14]. It is first initiated by the organism’s innate immune system that recruits 
cellular components such as monocytes (which can differentiate into macrophages,) 
granulocytes, dendritic cells and natural killer cells, to the site of infection or injury
[14, 15]
. 
These immune cells then recognise and eliminate potential pathogens typically through release 
and increased production of cytokines (figure 1). 
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Figure 1: Cellular components of the host response to invasive and cellular 
stress (adapted from Meneghin and Hogaboam, 2007
[16]
). Pathogen infection, 
along with tissue injury and cellular stress is known to induce a host response in 
order to provide effective clearance of pathogens and healing of the damaged sites. 
The innate immune system, consisting of cellular components such as monocytes, 
macrophages, dendritic cells and granulocytes (neutrophils, basophils and 
eosinophils), are activated and secrete immunomodulating proteins causing the 
protective inflammatory response. If inflammation persists however, due to 
ineffective clearance and dysregulation of the innate and adaptive (consisting of 
immune ‘memory’ cells, such as B and T cells) systems, chronic inflammation can 
occur, which underlies many inflammatory disorders.  
 
 
Cytokines are a diverse category of immunomodulating proteins that include interleukins, 
chemokines, interferons and tumour necrosis factors. These signalling proteins modulate the 
interactions and effects of target cells, which is crucial in producing a host response to 
invasive and damaging stimuli. Cytokines are divided into two general classes, pro- and anti-
Increased 
Cytokine Release 
Abnormal Innate 
and Adaptive 
Immune 
Response 
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inflammatory
[17]
, corresponding to their effect. Pro-inflammatory cytokines include molecules 
such as tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6). 
Principally produced from activated macrophages, their primary function is to elevate 
systemic inflammation inducing responses such as pyrexia, cachexia, cell death and 
pathological pain
[17]
. Conversely, anti-inflammatory cytokines such as interleukin-4 (IL-4), 
interleukin-10 (IL-10) and interleukin-11 (IL-11), act to regulate the pro-inflammatory 
response by suppressing pro-inflammatory cytokine expression and reduce neuropathic 
pain
[17]
. 
 
The inflammatory process in healthy individuals is tightly controlled by homeostatic 
processes, resulting in affective pathogen clearance and tissue healing procedures whilst 
preventing excessive inflammation
[1, 18]
. Acute inflammation however can develop into 
chronic systemic inflammation due to prolonged activation of the innate immune system and 
dysregulation of immune cells
[1]
, resulting in a sustained over-expression of pro-inflammatory 
cytokines.  
 
1.2.2 Cytokine Imbalance in Schizophrenia 
Recently, studies have investigated the role of cytokines and systemic inflammation in 
schizophrenia pathology
[14, 15, 19, 20]
. Results have shown a significant expression of pro-
inflammatory cytokines, their receptors and activity, above that of background levels, in the 
serum and cerebrospinal fluid of schizophrenia patients
[14]
. Cytokines are known to have 
additional roles other than regulating the immune system, as they are also important for 
communication between the immune and central nervous systems
[21]
 (CNS). Cytokines have a 
key function in neurodevelopmental processes such as synaptogenesis in foetal development 
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and regulation of synaptic plasticity, neurotransmission and neurogenesis in later life
[22, 23]
. It 
is believed that the immune response created from pre-natal viral exposure could subsequently 
interfere with brain development, and may result in an increased risk of developing 
schizophrenia
[24, 25]
. Therefore, imbalance in these key regulators could result in the 
neuroanatomical changes apparent in individuals with schizophrenia. Additionally, this may 
cause an abnormal and more aggressive inflammatory response from chronically activated 
monocytes and macrophages and an imbalance in T-cell subsets from the adaptive immune 
system
[15]
. Consequently, excessive release of cytokines could potentially contribute to many 
schizophrenia symptoms. Supporting this theory, studies have shown that peripheral 
administration of pro-inflammatory agents can induce the innate immune system to cause a 
‘sickness-behaviour’ which when persistent, can develop into negative symptoms such as 
social deficits and anhedonia
[1, 26]
, seen in schizophrenia. Table 1 shows a list of cytokines 
commonly altered in schizophrenia. 
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Cytokine Main Cellular Source Biological Function 
Effect in 
Schizophrenia 
IL-1β 
Activated 
monocytes/macrophages
, microglia and 
endothelial cells 
Promote fever, stimulate 
release of pro-
inflammatory cytokines, 
activation of T/B cells 
 (serum/plasma) 
/ (CNS) 
IL-2 T-cells (TH1) 
Activation, growth and 
differentiation of T-cells, 
stimulate natural killer 
cells and neutrophils to 
stimulate pro-
inflammatory cytokines. 
/--- (CNS) 
IL-6 
Activated monocytes and 
macrophages, T-cells 
(TH2/TH17) 
Promote fever, activate 
T-cells, stimulation of 
immunoglobulin-G 
production 
 (serum/plasma) 
IL-10 
Activated monocytes and 
macrophages, T cells 
(TH2), B-cells 
Inhibition of pro-
inflammatory cytokine 
synthesis, promotion of 
humoral immune 
repsonses 
 (serum/plasma) 
TNF-α 
Activated monocytes and 
macrophages, T-cells 
(TH1), natural killer cells, 
endothelial cells, 
microglia 
Promote fever, direct 
cytotoxic effects, 
activation on 
monocytes, lymphocytes 
and endothelial cells 
/ --- 
(serum/plasma)
 
Table 1: Cytokines implicated in the inflammatory response of schizophrenia 
(adapted from Meyer et al., 2011
[1]
). Table summarises a selection of cytokines, 
their main cellular source and biological functions found to be altered within the 
peripheral (serum/plasma) or central nervous systems (CNS) of schizophrenic 
patients. denotes a significant elevation,  s a significant reduction in 
cytokine levels. There is ambiguity however in some of the findings such as TNF-
α levels, as it has been found to be significantly elevated in some studies, however 
others have recorded a non-significant change (---).  
 
 
1.3 Role of Nicotinic Acetylcholine Receptors in Schizophrenia 
1.3.1 P50 Auditory Gating Deficits in Schizophrenia Patients 
Nicotinic acetylcholine receptors (nAChRs) are of particular interest within schizophrenia 
research as they have been implicated in numerous pathological and pathophysiological 
neurological functions such as learning and memory, attention and arousal and modulation of 
synaptic transmission
[27]
.  
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Nicotinic acetylcholine receptors are pentameric, ligand-gated ion channels consisting of a 
homomeric or heteromeric conformation from a selection of 16 subunits
[28]
. They are best 
known for their function in synaptic transmission following activation from endogenous 
neurotransmitter acetylcholine (ACh, figure 2). Nicotinic acetylcholine receptors are 
differentiated from muscarinic acetylcholine receptors as nAChRs can also be activated by the 
alkaloid, nicotine and other cholinergic agonists
[29]
.  
 
 
Figure 2: Acetylcholine receptor composition (adapted from Ulloa, 2005
[30]
 
and Erulkar and Lentz, 2013
[31]
). (A) Nicotinic acetylcholine receptors are either 
homomeric or heterometric pentamers consisting of a wide variety of subunits 
including α (1-10) β (1-4) γ, δ and ε subunits. Subunits co-assemble to create an 
array of subtypes which all have diverse biological and pharmacological 
A 
B 
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behaviours. Receptor affinity is related to the binding potential of receptor 
antagonist α-bungratoxin, which can specifically bind to neuronal nicotinic 
acetylcholine receptor α 1, 7 and 9 subunits. Nicotinic receptors can also exist in a 
homomeric conformation of α7 subunits. (B) Acetylcholine, and other nicotinic 
receptor agonists can bind to specific sites within the receptor subunits. This 
binding activates the receptor channel so it exists in an open conformation 
allowing positively charged ions, such as Na
+
, K
+
 and even Ca
2+
 to flow through 
the channel pore into the cell, mediating synaptic transmission. 
 
 
It has been documented that many cognitive deficits observed in neurological disease such as 
Parkinson’s disease and schizophrenia are often associated with attenuated cholinergic activity 
and deregulation of neuronal nAChRs
[28, 29]
. Major positive neurological indicators of 
schizophrenia include psychotic episodes with prominent auditory hallucinations (see section 
1.1). It is known that schizophrenia patients have deficits in neurological sensory (auditory) 
gating which filters out any redundant or superfluous stimuli from the surrounding 
environment, preventing flooding of extraneous information into the brain
[32]
. Individuals 
suffering from schizophrenia are unable to filter auditory stimuli that have been presented 50 
ms from one another whereas healthy individuals would generally regard the second stimuli to 
be redundant (figure 3)
[33]
. The P50 deficit has become one of the most recognized 
neurological markers concomitant with schizophrenia, as it is prominent in over 75% of 
patients
[33]
. 
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Figure 3: The P50 sensory gating deficit in schizophrenia (taken from 
Berrettini and Wade, 2005
[34]
).  Upon testing auditory sensory gating in 
individuals, 2 auditory stimuli are provided 50 ms apart. In healthy individuals, the 
evoked response, measured using scalp electrodes, to the second click is reduced 
in amplitude compared to the first click. This is to prevent overload of information 
into the brain and consequently the second stimulus is considered to be redundant 
since it occurs close to the first stimulus. This effect is considered to be the 
electrophysiological signature of sensory gating. In schizophrenic individuals 
however, the amplitude of the P50 wave of the second auditory stimulus is 
comparable to the first stimulus and is therefore considered to be a failure in 
sensory gating.  
 
 
It has been documented that stimulation of nAChRs via its agonist nicotine, can normalise and 
correct the P50 deficit
[33, 35].
 Epidemiological studies show that nicotine dependence is 
particularly high within schizophrenic individuals, as it has been reported that around 80% of 
patients
[36]
 frequently smoke compared to 25-30% of the general population
[37]
 suggesting that 
this in an effective self-medicated treatment for schizophrenia sufferers
[38]
. However, nicotine 
has only been shown to relieve the effects of abnormal sensory gating for around 30 minutes 
after which the deficit returns
[33]
, which could suggest why chain smoking is so prevalent 
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within patients
[39]
. Animal studies have shown that this gating deficit may be due to reduced 
function of nAChR in schizophrenia
[36]
. This is mirrored in post-mortem studies of brain tissue 
from schizophrenic individuals as a 50% reduction in the expression of low-affinity nicotinic 
acetylcholine receptors has been documented compared to healthy controls
[33, 36, 40]
. 
 
In addition to the function of nAChRs within the CNS, nicotinic AChRs have also been found 
to be expressed in non-neuronal cells, such as cells within the immune system, and are 
believed in play a role in the regulation of anti-inflammatory effects
[27]
.  
 
1.3.2 nAChRs in the Immune System 
The nAChRs expressed on component cells of the innate immune system, such as monocytes 
and macrophages, have recently been a focus within schizophrenia research
[15, 41, 42]
. 
 
The cholinergic anti-inflammatory pathway is particularly important within regulating the 
inflammation response as it acts as an endogenous mechanism to regulate overactive innate 
immune responses and prevent release of pro-inflammatory cytokines
[43]
, therefore attenuating 
the inflammation response so chronic inflammation does not occur. This reflex is induced 
upon increased levels pro-inflammatory cytokines, which can activate receptors situated on 
vagal nerves
[44]
. This inflammation response within the CNS can then alter the immune 
response through release of acetylcholine, which can significantly inhibit release of TNF-α 
and other pro-inflammatory cytokines from immune cells
[45, 46]
, figure 4.  
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Figure 4: Inhibition of pro-inflammatory cytokine release from macrophages 
via activation of nicotinic acetylcholine receptors (based on Ulloa, 2005
[30]
). 
Activation of the Vagus nerve, by stimuli such as cellular stress, causes release of 
the neurotransmitter acetylcholine, which consequently causes activation of 
nicotinic acetylcholine receptors present on immune cells such as macrophages, 
inhibiting the production of pro-inflammatory cytokines through reduced 
activation of the nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) pathway. Nicotine and nicotinic agonists have been shown to be more 
selective cholinergic agonists acting through α7nAChRs and are more effective at 
inhibiting pro-inflammatory cytokine release. 
 
 
Monocytes and differentiated macrophages have predominately been shown to be involved in 
release of pro-inflammatory cytokines within the innate immune system
[42]
.
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schizophrenia patients a noticeable increase in the number of monocytes has been 
documented
[42, 47]
. Additionally, irregularities in circulating monocytes have been seen within 
patients
[42]
, which could consequently result in increased release of pro-inflammatory 
cytokines, creating an elevated inflammatory response. Many studies however document that 
cytokine release from these cells is inhibited upon activation of the α7-homomeric nAChRs[44, 
48]. Therefore, because nicotine stimulation of α7-nAChRs has been shown to reduce pro-
inflammatory cytokine release and improve cognitive defects seen in schizophrenia 
patients
[49]
, further investigation concerning the role and therapeutic potential of nicotinic 
acetylcholine receptor agonists may provide a multimodal treatment for treatment and relief of 
schizophrenia symptoms.  
 
1.4 Contrasting Results Within Schizophrenia Research 
Many meta-analysis studies documenting cytokine levels in schizophrenia patients have 
reported a significant elevation in the serum, plasma and macrophage levels of pro-
inflammatory cytokines such as IL-1β, IL-6 and TNF-α[14, 20, 21]. However the strength of the 
conclusions from these studies may be questioned as cytokine release is affected by various 
factors, which are not consistently controlled for
[14, 15]
.  For example, the effects of current 
anti-psychotic medicine, such as clozapine, have been shown to elevate levels of TNF-α 
instead of reduce
[50]
. 
 
Additionally, many studies have recorded cytokine levels from different stages of disease 
progression and therefore some patients may have had longer exposure to anti-psychotic 
medicines, which would affect data analysis
[14]
. Other studies have aimed to correct for this by 
investigating patients that have experienced their first psychotic episode (first-episode 
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psychosis; FEP) although many patients have actually recently commenced treatment or 
analysed in a ‘drug-free’ state, however been previously taken medication[14, 19]. Therefore it is 
important when investigating the true effects of inflammation in schizophrenia, that FEP 
patients who are neuroleptic-naïve and have never commenced treatment are studied.  
 
Other patient demographics such as illicit drug use
[51, 52]
 age
[21]
, gender
[14]
 body mass index 
(BMI)
[53]
 and smoking-status
[54]
 are also known to dramatically affect levels of pro-
inflammatory cytokines in patient blood and historically have not always been accounted for 
during studies. The BMI of a patient for example, is important when measuring cytokine 
levels as it is known that obesity can cause an inflammatory response in many metabolic 
tissues
[53, 55]
. Consequently, systemic cytokine levels have been shown to be considerably 
elevated in obese individuals, therefore not providing a true representation of cytokine level in 
regards to schizophrenia. Furthermore, as previously discussed, nicotine plays a large role in 
self-medication of schizophrenia patients
[56]
, resulting in a reduced inflammatory response, 
again obscuring the true cytokine response as a result of schizophrenia. 
 
TNF-α is one of the most common pro-inflammatory cytokines researched and dysregulation 
of TNF-α levels have been associated with diseases such as Alzheimer’s[57] and inflammatory 
bowel disease
[58]
. Within schizophrenia however, there is ambiguity over the regulation of 
TNF-α. A large number of studies have documented TNF-α elevation in patients[1, 19, 41, 59] 
however other studies have shown no significant alteration
[21]
. This uncertainty could be a 
result from the influence of the above factors that may have not been controlled for. Therefore 
to improve success of future research in resolving schizophrenia aetiology and developing 
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potential treatments, it is imperative that differential expression of TNF-α is first elucidated 
using FEP neuroleptic-naïve patients who are demographically matched to healthy individuals.  
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2. AIMS AND HYPOTHESES 
2.1 Aims 
The aims of this project were to: 
 Investigate TNF-α release from stimulated monocytes harvested from whole blood 
obtained from 10 neuroleptic-naïve FEP patients and compare to 9 healthy individuals 
which had been matched for age, gender, BMI and smoking-status.  
 Use an in vitro culture model, representative of primary monocytes, to observe any 
differences in monocytic TNF-α release in the presence of a variety of 
pharmacological compounds. 
 
2.2 Hypotheses 
It was hypothesised that, according to previous research, TNF-α levels produced from 
stimulated monocytes, will be increased amongst the schizophrenia patients compared to the 
healthy controls. The use of FEP neuroleptic-naïve cases (demographically matched with the 
control samples) in this study will provide a better representation of the differential expression 
of TNF-α associated with schizophrenia and a greater understanding of the role of 
inflammatory cytokines in this disease. Additionally, through the use of a monocytic cell line, 
the TNF-α levels released from stimulated cells are likely to be altered within the presence 
anti-psychotic drugs and nAChR agonists, and could therefore be investigated further as 
potential anti-inflammatory treatments for schizophrenia. This would be of significant benefit 
since many atypical antipsychotics, such as clozapine, are associated with serious side-effects 
and can potentially increase TNF-α levels over time.  
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3. MATERIALS AND METHODS 
 
3.1 Cell Culture 
 
THP-1 cells, a human monocytic cell line, were cultured in suspension in RPMI-1640 medium 
(containing L-Glutamine and sodium bicarbonate; Sigma-Aldrich, R8758) supplemented with 
10% heat-inactivated foetal bovine serum (HI-FBS) and 1% penicillin/streptomycin 
(Pen/Strep). Cultures were incubated at 37˚C, 5% CO2.  
 
3.2 LPS Stimulation of THP-1 Cells  
The endotoxin lipopolysaccharide (LPS; Sigma-Aldrich, L2630) from Escherichia coli is a 
major inducer of TNF-α and was used to stimulate THP-1 cells to produce an inflammatory 
response. THP-1 cells were centrifuged at 400 G, 5 minutes, after which the supernatant was 
removed and cell pellet suspended in RPMI-1640 (10% HI-FBS, 1% Pen/Strep).  Cells were 
counted using a haemocytometer and seeded into a 48-well plate at a density of 2.5 x 10
5
 cells 
per well. To determine the optimal stimulation time and LPS concentration which would 
evoke optimum TNF-α production, cells were stimulated at 37˚C, 5% CO2 with 0, 1, 10 and 
100 ng/mL LPS for 1, 2, 4, 8 and 24 hours. At each time point, the cell suspension was 
removed and centrifuged (300 G, 5 minutes). The supernatant was then transferred, taking care 
to not disturb the THP-1 pellet, to a new 48-well plate and kept at -80˚C until needed to 
quantify TNF-α concentration using Enzyme-Linked Immunosorbent Assay (ELISA) analysis 
(see section 3.7).  
 
3.3 THP-1 Stimulation in the Presence of a Range of Pharmacological Agents 
Following determination of the optimal LPS concentration and stimulation time, THP-1 cells 
were stimulated with LPS and a range of drugs to observe any changes in TNF-α production. 
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THP-1 cells were seeded at density 2.5 x 10
5
 cells per well onto two 48-well plates, which 
were stimulated (one plate with 10 ng/mL the other with 100 ng/mL LPS) for 4 hours (37˚C, 
5% CO2). Table 2 shows the drug concentrations and corresponding vehicle control used.  
 
Drug 4BP-TQS 
5-HT and 5-
Chloroindole 
PNU 282987 
and PAM 
120596 
Clozapine 
Concentration 
(µM) 
30 
3 (5-HT) 
10 (5-chloroindole) 
10 (PNU) 
1 (PAM) 
1 
Vehicle Control 0.3 % DMSO 0.1 % DMSO 0.1 % DMSO 0.01% Water 
 
Table 2: Concentrations of pharmacological agents used to assess TNF-α 
levels from LPS- stimulated THP-1 cells. Table showing the concentrations at 
which the agents in this study, (4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS), 5-HT (serotonin), 5-
Chloroindole, PNU-282987, PAM-120598, and clozapine were used, with the 
corresponding vehicle control, dimethyl sulfoxide (DMSO) or water, for each 
condition. Each condition was replicated 5 times. 
 
Following 4-hour stimulation, plates were centrifuged (300 G, 5 minutes) and supernatants 
removed and stored at -80˚C until cytokine quantification.  
 
3.4 THP-1 Stimulation in the Presence of 4BP-TQS 
3.4.1 4BP-TQS Concentration Curve 
A concentration curve was produced to determine the lowest but effective concentration of 
4BP-TQS. The minimum effective concentration is important to determine to ensure the effect 
is due to the drug and not from high cytotoxic concentrations.  THP-1 cells were seeded into a 
48-well plate at a density of 2.5 x 10
5
 cells per well. Table 3 shows the concentrations and 
vehicle controls used.  
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Condition 4BP-TQS Cycloheximide Stimulation Control 
Concentration 
(µM) 
1 3 10 30 100 25 - 
Vehicle 
Control 
1% DMSO 0.25% Ethanol - 
LPS 100 ng/mL 100 ng/mL 100 ng/mL 
 
Table 3: 4BP-TQS concentration curve. 1, 3, 10, 30 and 100 µM of 4BP-TQS 
was added to THP-1 cells.  1% DMSO was added to serve as a vehicle control for 
4BP-TQS. 100 ng/mL of LPS was added to all conditions to stimulate the cells. 
100 ng/mL LPS was also added to cells in the absence of 4BP-TQS to serve as a 
stimulation control.  In addition, cells were also stimulated with 25 µM 
cycloheximide (Sigma-Aldrich, C7698) and 100 ng/mL LPS to act as a positive 
control of cell death to check cell viability using fluorescent-activated cell sorting 
(FACS). A 0.25% ethanol vehicle control was used. Each condition was performed 
in triplicate. 
 
Cells were incubated (37˚C, 5% CO2) for 4 hours. Following incubation, the plate was 
centrifuged (300 G, 5 minutes) after which supernatants extracted and kept at -80˚C until 
TNF-α quantification. THP-1 cell pellets were suspended in phosphate-buffered saline (PBS) 
and taken for fluorescent-activated cell sorting (FACS) analysis (described in section 3.5) to 
check cell viability.  
 
3.4.2 THP-1 Stimulation With 4BP-TQS and Picrotoxin 
To investigate whether the effect of 4BP-TQS on THP-1 TNF-α release could be blocked, 
varying concentrations of picrotoxin (PTX) was added in combination with 30 µM 4BP-TQS. 
THP-1 cells were seeded in a 48-well plate at a density of 2.5 x 10
5
 cells per well. Table 4 
shows the concentrations and vehicle controls for each condition. 
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PTX 300 nM 1 µM 3 µM 3 µM - 
4BP-TQS 30 µM 30 µM 30 µM - 30 µM 
Vehicle 
control 
0.3 % DMSO 
LPS 
Stimulation 
100 ng/mL 100 ng/mL 100 ng/mL - 100 ng/mL 
 
Table 4: Concentrations of PTX used in combination with 4BP-TQS. Table 
shows concentrations of PTX added to THP-1 cells stimulated with 100 ng/mL 
LPS in combination with 30 µM 4BP-TQS. 3 µM PTX was added to cells without 
4BP-TQS and LPS stimulation, to ensure that the PTX was not causing an effect 
on the TNF-α release. Similarly, 100 ng/mL LPS was added in the absence of 
4BP-TQS and PTX to serve as a stimulation control. Each condition was 
performed in triplicate. 
 
Cells were then stimulated accordingly and incubated (37˚C, 5% CO2) for 4 hours. Following 
stimulation, the plate was centrifuged (300 G, 5 minutes) after which supernatants were 
extracted and stored at -80˚C until needed.  
 
3.4.3 THP-1 Stimulation With 4BP-TQS and Methyllycaconitine  
THP-1 cells were stimulated with 4BP-TQS and methyllycaconitine (MLA) to see if the effect 
of 4BP-TQS could be inhibited. THP-1 cells were seeded in a 48-well plate at a density of 2.5 
x 10
5
 cells per well. Table 5 shows drugs concentration and vehicle controls used. 
 
Drug 4BP-TQS MLA 4BP-TQS and MLA 
Concentration 10 µM 100 nM 
10 µM (4BP-TQS) 
100 nM (MLA) 
Vehicle Control 0.1% DMSO 0.01% Water 0.1% DMSO and 0.01% Water 
 
Table 5: Concentrations of MLA and 4BP-TQS incubated with LPS-
stimulated THP-1 cells. Table showing concentrations of MLA and 4BP-TQS 
added to 100 ng/mL LPS-stimulated THP-1 cells and the appropriate vehicle 
control for each condition. 100 ng/mL LPS was added in the absence of 4BP-TQS 
and MLA to serve as a stimulation control. Each condition was replicated 5 times. 
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Cells were then stimulated with 100 ng/mL LPS and incubated (37˚C, 5% CO2) for 4 hours. 
Following stimulation, the plate was centrifuged (300 G, 5 minutes) after which supernatants 
were extracted and stored at -80˚C until needed.  
 
3.5 Fluorescent-Activated Cell Sorting (FACS) 
 
To ensure that concentrations of 4BP-TQS were not toxic to THP-1 cells, thereby affecting 
TNF-α release, THP-1 cell viability was checked via FACS following 4BP-TQS stimulation. 
 
After stimulation for 4 hours (section 3.4.1), cells were centrifuged at 300 G, 5 minutes. 
Supernatants were then removed and kept for ELISA analysis.  The resulting THP-1 cell 
pellets were suspended in 270 µL PBS/2% bovine serum albumin (BSA). The cell suspension 
was transferred to a FACS tube where 30 µl of SYTOX Blue (final concentration of 0.125 
µM; Life Technologies, S34857) was added for 5 minutes. SYTOX Blue dead cell stain is able 
to penetrate and stain nucleic acid in cells with comprised plasma membranes. When a 405 nm 
violet laser is shone on the sample, the nucleic acids within the dead cells fluoresce, and is 
detected in the violet channel of the CyAn Advanced Digital Processing (ADP) High-
Performance Flow Cytometer (Beckman-Coulter).  Figure 5 shows an example of SYTOX 
Blue fluorescence. 
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Figure 5: SYTOX Blue dead cell stain (taken from Life Technologies
[60]
). 
Schematic shows fluorescence of cells analysed on a flow cytometer equipped 
with a 405 nm violet diode laser. The dead cell population can easily be 
distinguished from the live cells by a sharp peak around 10
4
. 
 
The forward and side scatter of the cells was measured for each of the samples and the 
fluorescence from the SYTOX Blue recorded. Data generated was consequently imported and 
processed using Summit software (v4.3, Beckman-Coulter), where the mean percentage of cell 
death was determined for each condition.  
 
3.6 Peripheral Blood Mononuclear Cell (PBMC) Purification 
3.6.1 Monocyte Purification Using Ficoll-Paque and Plastic Adherence Methods  
Blood was acquired from 10 patients with medication-naïve FEP, meeting research diagnostic 
criteria for schizophrenia
[61]
, and 9 demographically controlled individuals, matched for age, 
gender, body mass index (BMI) and smoking-status. Blood was collected in vacutainers 
coated with an anti-coagulant EDTA, to prevent blood clotting. Blood samples were blinded 
and sent to the laboratory to harvest monocytes using the Ficoll-Paque density gradient 
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centrifugation method. Ficoll-Paque allows separation of blood components by density, 
forming distinctive layers of component blood cells, which can then be individually isolated.  
Whole blood was carefully layered on top of 25 mL Ficoll-Paque (GE healthcare, 17-1440-
03), in a 50 mL conical tube. It is important there is minimal mixing of the two layers to 
obtain good separation of the blood. The sample was then centrifuged (900 G (no brake), 25 
minutes). Following centrifugation, the blood was seen to clearly separate into its different 
constituent parts (figure 6).  
 
 
 
 
 
 
 
 
 
Figure 6: Ficoll-Paque density centrifugation of whole blood (taken from 
Munoz and Leff, 2007
[62]
). Following centrifugation at 900 G for 25 minutes, 
whole blood is separated by density allowing clear identification of its constituent 
parts. To harvest peripheral blood mononuclear cells, the plasma/serum fraction is 
removed and the underlying PBMC layer is removed and subsequently purified to 
obtain primary monocytes.  
 
The plasma layer was carefully removed and kept for future analysis. The PBMC layer 
underneath was harvested and transferred to a new conical tube. RPMI-1640 (1% Pen/Strep) 
was then added to top up the PBMC fraction to 50 mL. The sample was then centrifuged (400 
G, 5 minutes). The supernatant was subsequently removed, leaving the PBMC pellet. The 
pellet was then suspended in 50 mL RPMI-1640 (1% Pen/Strep), and centrifuged (400 G, 5 
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minutes). This step was repeated until the medium was clear (approximately 2 washes). The 
washes are important to remove any contaminating Ficoll-Paque, platelets and plasma 
proteins. Following the final wash, the supernatant was removed and the PBMC pellet was 
suspended in 1 mL RPMI-1640 (+10% HI FBS, 1% Pen/Strep) and cells counted. For 
monocyte purification, cells were suspended to a density of 3 x 10
6
 cells/mL and 500 µL was 
added to each well of a 48-well plate. Cells were then incubated (37˚C, 5% C02) for 1 hour so 
that the monocytes could adhere. Following incubation, the medium was removed and 
monocytes were washed three times with 500 µL RPMI-1640 (+10% HI FBS, 1% Pen/Strep), 
to rid of any contaminant cells such as lymphocytes.  
 
3.6.2. LPS Stimulation of Monocytes 
Following purification, adhered monocytes were stimulated with 10 ng/mL LPS for 24 hours. 
Following incubation, plates were centrifuged (300 G, 5 minutes). The supernatant was then 
removed and kept at -80˚C until needed for ELISAs. Samples required processing 24 hours 
after they were obtained and were collected over a 12-month period. Previously 14 out of 19 
samples had been collected, processed in the lab, and stimulated supernatants had been frozen 
until analysed simultaneously for TNF-α levels.  
 
3.7. Enzyme-Linked Immunosorbent Assay (ELISA) 
3.7.1. ELISA Protocol 
ELISAs were performed to detect the concentration of human-TNF-α released from the THP-1 
stimulation experiments and schizophrenia patient and control monocytes.  
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ELISAs were conducted according to manufacturers instructions (ELISA Human TNF-α 
Max
TM
; Biolegend, 430201). First, a 96-well plate was coated in 100 µl of capture antibody 
(1:200 dilution in 1x coating buffer) and incubated overnight (4˚C). Following incubation, the 
plate was washed four times with wash buffer (1x PBS + 0.05% Tween). 200 µl of 1x assay 
diluent (10% FBS in PBS) was added to each well and incubated at room temperature (RT) for 
1 hour with shaking. This was to block any non-specific antibody binding. The plate was then 
washed four times with wash buffer. Following, 100 µL of TNF-α standards and samples 
(which had been diluted in 1x assay diluent to be in the ELISA detection range) were added to 
the appropriate wells and incubated at RT for 2 hours with shaking. After incubation, the 
plates were washed four times with wash buffer. 100 µL of detection antibody (1:200 dilution 
in 1x assay diluent) was added to each well and incubated at RT for 1 hour with shaking. The 
plate was then washed four times with wash buffer. 100 µL of diluted Avidin-HRP solution 
(1:1000 dilution in 1x assay diluent) was then added to each well and incubated at RT for 30 
minutes with shaking. After, the plates were washed five times, soaking the plates for 30 
seconds per wash. Finally 100 µL of TMB substrate solution (Bethyl Laboratories, 130221) 
was added to each well and incubated in the dark for between 10-25 minutes, until the desired 
colour had developed. To stop the reaction, 100 µL of stop solution (2 N H2SO4) was added to 
each well. The absorbance was then read on a microplate reader (Multiskan EX, Thermo) at 
450 nm.  
 
3.7.2. ELISA Analysis 
Data was imported into GraphPad Prism software, v6 for Macintosh (GraphPad Software, La 
Jolla California USA), where a linear regression was performed of a standard curve, which 
was calculated from known concentrations of TNF-α run in duplicate, on each ELISA plate. 
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TNF-α concentration (pg/mL) of unknown samples was then determined by interpolation with 
the standard curve. The identity of the samples was unknown until all samples had been 
processed.  
 
3.8. Analysis and Statistics 
All statistical tests were performed using GraphPad Prism. A Shapiro-Wilk test was performed 
to determine if the data was of normal distribution. A parametric unpaired T-test, assuming 
unequal standard deviation (SD; with Welch’s correction) or non-parametric Mann-Whitney 
test was then performed. Normalised data was analysed by a one-sample t-test. Any outliers 
within the data were identified by performing a ROUT (1%) test and subsequently omitted 
from analysis. FACS analysis was performed using Summit (v.4.3, Beckman Coulter).  
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4. RESULTS 
4.1 Optimisation of LPS Stimulation of THP-1 Cells.  
To determine the optimal TNF-α release from THP-1 cells, the optimum stimulation time and 
LPS concentration had to be determined to be within the detection range for ELISA analysis.  
It can be seen in figure 7 that as expected in the absence of LPS, TNF-α release was below the 
level of detection. Similarly, with addition of 1 ng/mL LPS, there was minimal release from 
all time points. However, when 10 ng/mL LPS was added there was a considerable increase in 
TNF-α that peaked at 4 hours (222.6±43.6 pg/mL) however substantially decreased after 24 
hours (34.2±8.9 pg/mL). The largest increase in TNF-α concentration however was seen upon 
stimulation with 100 ng/mL LPS for 4 hours (508.4±86.4 pg/mL) which again decreased to 
considerably lower levels following 24 hours (96.3±44.9 pg/mL). Therefore, in future 
experiments stimulation with 10/100 ng/mL LPS for 4 hours was chosen. 
 
 
Figure 7: TNF-α release from THP-1 cells with varying concentrations of 
LPS. THP-1 cells were seeded at a density of 2.5 x 10
5
 cells per well of a 48-well 
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plate. Cells were then stimulated with either 0, 1, 10 and 100 ng/mL of LPS and 
incubated at 37˚C. The supernatant was collected at various time points during the 
stimulation period and ELISAs were used to determine TNF-α levels at each time 
point. It is clear that THP-1 cells were not stimulated in the absence of LPS since 
no TNF-α was released. Stimulation with 1 ng/mL LPS only elicited a small 
response, which peaked at 4 hours (16.9±5.7 pg/mL). There was a noticeable 
increase in TNF-α release when cells were stimulated with 10 ng/mL LPS, which 
again peaked at 4 hours (222.6±43.6 pg/mL) and declined after 24 hours (34.2±8.9 
pg/mL). The largest TNF-α release was seen upon stimulation with 100 ng/mL 
LPS and again peaked after 4 hours stimulation (508.4±86.6 pg/mL) and similarly 
declined after 24 hours (96.3±44.9 pg/mL). Samples had not been diluted for 
ELISA analysis. Data was obtained from 3 independent experiments, with each 
time point conducted in duplicate. Any outliers were identified using a ROUT test 
(1%) and subsequently removed. Error bars represent ± standard error of the mean 
(SEM).  
 
 
4.2 TNF-α Release From LPS-Stimulated THP-1 Cells Incubated With a Range of 
Pharmacological Agents. 
Stimulated THP-1 cells were incubated with a range of pharmacological agents to see if TNF-
α release could be altered. When THP-1 cells were stimulated with 10 ng/mL LPS and 
incubated with 30 µM 4BP-TQS for 4 hours (figure 8(i)), there was a significant (p=0.002) 
decrease in TNF-α release compared to control (0.3% DMSO). Upon addition of 5-HT and 5-
Chloroindole and PNU and PAM, there was no significant decrease in TNF-α concentration 
compared to vehicle control (0.1% DMSO). There was a small but insignificant decrease in 
TNF-α release however, upon addition of 1µM clozapine.  The results from each condition 
were normalised to the vehicle control (figure 8(ii)). Again, there is a distinctive decrease 
when THP-1 cells were incubated in the presence of 30 µM 4BP-TQS (p=0.01). There was no 
significant difference when cells were incubated with 5-HT and 5-Chloroindole or PNU and 
PAM. Clozapine induced a significant reduction (p=0.04) in TNF-α when normalised between 
experiments. 
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Cells were also stimulated with 100 ng/mL LPS for 4 hours and again the same trend in TNF-
α release with 10 ng/mL can be seen (figures 8 (iii) and (iv)). Incubation with 30 µM 4BP-
TQS caused a significant (p=0.0001) decrease in TNF-α concentration released from 
stimulated THP-1 cells. Again there was no change when cells were incubated with 5-HT and 
5-Chloroindole but there was a significant decrease (p=0.05) in TNF-α release with addition of 
PNU and PAM. There was a slight decrease when cells were incubated with clozapine 
however was not significant.  When these results were normalised to the vehicle control for 
each condition (figure 8 (iv)), it is again apparent that 30 µM 4BP-TQS caused a significant 
reduction in TNF-α release from THP-1 cells (p=0.01). Large variability between experiments 
was seen when cells were incubated with 5-HT and 5-Chloroindole or PNU and PAM. Again a 
slight decrease in TNF-α concentration was seen with clozapine incubation, however was not 
significant. 
  
2
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Figure 8: TNF-α release from LPS-stimulated THP-1 cells in the presence of 
a variety of pharmacological agents. (i) THP-1 cells stimulated with 10 
ng/mL LPS for 4 hours. A significant decrease (p=0.002) was observed upon 
incubation with 4BP-TQS when compared to the 0.3% DMSO vehicle control 
(0.3%DMSO: 78.7±11.9 pg/mL; 30 µM 4BP-TQS: 38.0±7.6 pg/mL). No other 
significant differences were seen in TNF-α release with the other agents compared 
to their respective controls (0.1% DMSO: 68.3±7.9 pg/mL; 3 µM 5-HT+ 10 µM 
5-Chloroindole:  63.2±9.1 pg/mL; 10 µM PNU + 1 µM PAM: 65.4±9.1 pg/mL 
and 0.01% Water: 80.9±12.5 pg/mL; 1 µM Clozapine: 66.4±11.3 pg/mL). (ii) 
Normalisation of TNF-α levels to the vehicle control. The data was then 
subsequently normalised to the corresponding vehicle control within each 
experiment performed. Again a significant decrease was seen upon incubation 
with 30 µM 4BP-TQS (p=0.01). Also a significant decrease was seen in TNF-α 
release when incubated with 1 µM clozapine (p=0.04). (iii) THP-1 cells 
stimulated with 100 ng/mL LPS for 4 hours. A significant decrease (p= 0.0001) 
was seen when incubated with 30 µM 4BP-TQS compared to the 0.3% DMSO 
vehicle control (0.3% DMSO: 191.1±13.4 pg/mL; 30 µM 4BP-TQS; 106.3±11.8 
pg/mL). A significant decrease (p=0.05) was also seen when 1µM PNU and 10 
µM PAM was incubated with stimulated THP-1 cells compared to the vehicle 
control (0.1% DMSO: 173.7±14.2 pg/mL; 10 µM PNU+ 1 µM PAM: 137.2±10.5 
pg/mL). No significant decrease was seen when incubated with 3 µM 5-HT+ 10 
µM 5-Chloroindole however (3 µM 5-HT+ 10 µM 5-Chloroindole: 164.4±7.4 
pg/mL) or with 1 µM Clozapine, compared to the vehicle control (0.01% Water: 
180.2±13.1 pg/mL; 1 µM Clozapine: 158.1±13.7 pg/mL). (iv) Normalisation of 
TNF-α levels to the vehicle control. A significant decrease in TNF-α release is 
again apparent following incubation with 4BP-TQS (p=0.01), but not with any of 
the other compounds. Samples had been diluted 1:4 to be in the detection range 
for ELISA analysis. Data was obtained from 3 independent experiments, with 
each condition replicated 5 times in each experiment. Any outliers were identified 
using a ROUT (1%) statistical test and subsequently removed. For graphs 
presenting all data points, error bars represent ±SEM and normalised data graphs 
represent ± SD.  
 
 
4.3 THP-1 Stimulation With 4BP-TQS and PTX 
 
Following identification that 4BP-TQS reduced significantly TNF-α from LPS-stimulated 
THP-1 cells, an experiment was conducted to see if this response could be inhibited. THP-1 
cells were stimulated with 100 ng/mL LPS for 4 hours in the presence of 30 µM 4BP-TQS 
and a range of concentrations of PTX. It is apparent that upon addition of 300 nM, 1 and 3 
µM PTX, TNF-α release was reduced to a similar level seen with 30 µM 4BP-TQS, compared 
to vehicle control (0.3% DMSO), therefore showing the effect of 4BP-TQS was not inhibited 
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(figure 9(i)). To check that PTX alone was not altering TNF-α release, THP-1 cells were 
incubated solely with 3 µM PTX and it is apparent that there was minimal TNF-α release. 
Results were normalised to the vehicle control and again it can be seen that upon addition of 
PTX, TNF-α concentration remained reduced and was not rescued to values similar to the 
vehicle control (figure 9 (ii)).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(i) 
(ii) 
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Figure 9: Incubation with PTX and 30 µM 4BP-TQS does not inhibit TNF-α 
from 100 ng/mL LPS-stimulated THP-1 cells. (i) Upon incubation with 300 
nM, 1 and 3 µM PTX and 30 µM 4BP-TQS, there was no significant increase in 
TNF-α levels compared to the 0.3% DMSO vehicle control (0.3% DMSO: 
305.1±67.8 pg/mL; 300 nM PTX+ 30 µM 4BP-TQS: 175.3±47.2 pg/mL; 1 µM 
PTX+ 30 µM 4BP-TQS: 150.7±40.8 pg/mL; 3 µM PTX+ 30 µM 4BP-TQS: 
142.7±38.4 pg/mL) and to 30 µM 4BP-TQS alone (30 µM 4BP-TQS: 151.6±27.4 
pg/mL). TNF-α levels were measured from THP-1 cells that had been incubated 
with 3 µM PTX in the absence of 100 ng/mL LPS stimulation to confirm that 
PTX did not cause a direct effect on THP-1 cells. It can be seen that cells were not 
affected since TNF-α was not produced in absence of stimulation (3 µM PTX: 
2.2±1.4 pg/mL). (ii) Data was normalised to the vehicle control and it is apparent 
that incubation with PTX in combination with 30 µM 4BP-TQS did not inhibit the 
reduction in the levels of TNF-α which is caused by 4BP-TQS. A significant 
reduction was seen between the control and 3 µM PTX and 30 µM 4BP-TQS 
(p=0.01). Samples had been diluted 1:4 to be in the detection range for ELISA 
analysis. Data was obtained from 3 independent experiments (1 experiment for 30 
µM 4BP-TQS alone). Each condition was performed in triplicate within each 
experiment. Any outliers were identified using a ROUT (1%) statistical test and 
subsequently removed. Error bars in graphs showing all data points (i) represent ± 
SEM and normalised data (ii) represent ± SD. 
 
 
4.4 4BP-TQS Concentration Curve 
 
To determine the minimum concentration of 4BP-TQS needed to cause a reduction in TNF-α, 
THP-1 cells were stimulated (100 ng/mL LPS, 4 hours) in the presence of 1, 3, 10, 30 and 100 
µM 4BP-TQS.  Figure 10 shows that 1 µM 4BP-TQS increased the TNF-α concentration 
compared to the vehicle control (0.1% DMSO). However 3, and 10 µM had a slight decrease 
in TNF-α release and it is clear that 100 µM 4BP-TQS had the largest reduction in TNF-α. 
There is large variability within the results however so replications are needed.  
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Figure 10: TNF-α levels from LPS-stimulated THP-1 cells incubated with 
increasing concentration of 4BP-TQS.  It is apparent that upon incubation with 
1 µM 4BP-TQS (255.2±92.0 pg/mL), there is an increase in the TNF-α levels 
compared to the 0.1% DMSO control (156.7±88.2 pg/mL) indicating this 
concentration of 4BP-TQS is not sufficient to reduce TNF-α release. There is a 
slight decrease upon application with 3 (136.2±57.3 pg/mL) and 10 µM 
(155.3±57.3 pg/mL) but increase with 30 µM 4BP-TQS (167.3±122.8 pg/mL). 
The largest and consistent reduction in TNF-α concentration was seen however 
with 100 µM 4BP-TQS (31.6±31.6 pg/mL). Large variability is seen within the 
other concentrations and should therefore be repeated. Samples were diluted 1:4 
to be in the detection range for ELISA analysis. Data was obtained from 1 
independent experiment. Each condition was repeated in triplicate. Error bars 
represent ± SEM.  
 
 
4.5 Confirmation of Cell Viability Following 4BP-TQS Incubation 
 
To confirm that 4BP-TQS was not toxic to THP-1 cells during the 4-hour stimulation, cell 
viability was measured using SYTOX Blue staining and analysed by flow cytometry. Figure 
11 shows forward and side scatter plots of THP-1 cells for each condition and histograms 
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documenting the fluorescence emission from SYTOX Blue, indicating the percentage of dead 
cells. Gating was applied to distinguish THP-1 cells. It is clear that there was less than 1% 
cell death exhibited in all conditions.  
  
 
 
Condition 
100 
ng/mL 
LPS 
1% 
DMSO 
1 µM 
4BP-
TQS 
3 µM 
4BP-
TQS 
10 µM 
4BP-
TQS 
30 µM 
4BP-
TQS 
100 µM 
4BP-
TQS 
25 µM 
Cyclohex
-imide 
0.25% 
Ethanol 
Average Cell 
death (%) 
0.32 0.24 0.23 0.20 0.79 0.94 0.45 0.61 0.19 
100 ng/mL LPS only 1% DMSO 
1 µM 4BP-TQS 3 µM 4BP-TQS 
10 µM 4BP-TQS 30 µM 4BP-TQS 
100 µM 4BP-TQS 25 µM Cycloheximide 
0.25% Ethanol 
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Figure 11: Flow cytometry was used to assess cell viability following 4BP-
TQS incubation. Following 4-hour stimulation, THP-1 cells were stained with 
SYTOX blue to assess cell viability in the various conditions. It is apparent that 
less than 1% cell death was exhibited. 25 µM cycloheximide (and its vehicle 
control 0.25% ethanol) was used as a positive control for cell death, as it is a 
known inhibitor of protein synthesis. However cell death was not exhibited in this 
condition. The granularity of the cells however has been significantly altered, 
indicated by the increased side scatter of the cells. Data was obtained from 1 
independent experiment, in which each condition was replicated 5 times.  
 
 
4.6 THP-1 Stimulation With 4BP-TQS and MLA  
 To observe whether 4BP-TQS-induced reduction in TNF-α release from THP-1 cells could 
be blocked, cells were stimulated with 100 ng/mL LPS for 4 hours in presence of a potent 
nAChR antagonist, MLA. It is clear from figure 12(i) that there was a reduction in TNF-α 
upon incubation with 10 µM 4BP-TQS compared to the vehicle control (0.1% DMSO), 
however this did not achieve statistical significance. When THP-1 cells were incubated with 
10 µM 4BP-TQS and 100 nM MLA however, TNF-α concentration was comparable to 
vehicle control levels (0.1% DMSO and 0.01% water). Upon application of 100 nM MLA, 
TNF-α was significantly (p=0.05) reduced compared to the vehicle control (0.01% water).  
 
When results were normalised to vehicle controls (figure (ii)), it was again apparent that upon 
incubation with 10 µM 4BP-TQS that TNF-α concentration was reduced in comparison to the 
vehicle control but levels were increased when 100 nM MLA was added in combination with 
10 µM 4BP-TQS. Incubation with 100 nM MLA was shown to reduce TNF-α release from 
THP-1 cells, however large variability between experiments is shown.  
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Figure 12: TNF-α release from 100 ng/mL LPS-stimulated cells in the 
presence of a potent nAChR antagonist. (i) Incubation of stimulated THP-1 
cells with 10 µM 4BP-TQS showed a decrease in TNF-α release, however was not 
significant compared to the 0.1% DMSO vehicle control (0.1% DMSO: 
163.3±40.5 pg/mL; 10 µM 4BP-TQS: 147.7±42.1 pg/mL). An increase in TNF-α 
levels was seen however upon co-incubation with 100 nM MLA compared to 10 
µM 4BP-TQS incubation alone and similar levels were seen to the 0.1%DMSO+ 
0.01% water vehicle control (0.1%+ 0.01% water: 219.1±75.0 pg/mL; 10 µM 
4BP-TQS+ 100 nM MLA: 228.2±44.8 pg/mL). A significant decrease (p=0.05) 
was seen upon incubation of stimulated cells with 100 nM MLA alone, compared 
to the 0.01% water vehicle control (0.01% water: 225.1±68.9 pg/mL; 100 nM 
MLA: 59.4±25.6 pg/mL). (ii) Data from each condition was normalised to the 
(i) 
(ii) 
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vehicle control for each experiment performed. It is clear that incubation with 10 
µM 4BP-TQS caused a reduction in TNF-α release, which was restored when 100 
nM MLA was incubated in combination. There was a decrease in TNF-α levels 
upon incubation with 100 nM MLA alone, however a large variability between 
experiments is evident. Samples were diluted 1:4 to be in the detection range for 
ELISA analysis. Data was obtained from 2 independent experiments. Each 
condition was replicated 5 times within each experiment. Any outliers were 
identified using a ROUT (1%) statistical test and subsequently removed. Error 
bars in graphs showing all data points (i) represent ± SEM and normalised data 
(ii) represent ± SD.  
 
 
4.7 TNF-α Concentration Released From Neuroleptic-Naïve FEP Patients and Control 
LPS-Stimulated Monocytes. 
Monocytes were harvested from whole blood samples obtained from 10 FEP patients and 9 
controls, and stimulated with 10 ng/mL LPS for 24 hours. TNF-α production was measured 
using ELISAs (figure 13).  
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Figure 13: TNF-α release from LPS-stimulated monocytes obtained from 
neuroleptic-naïve FEP patients and control individuals. Primary monocytes 
were harvested from whole blood obtained from 10 FEP neuroleptic-naïve 
schizophrenic patients and 9 healthy controls. Monocytes were then stimulated 
with 10 ng/mL LPS for 24 hours. Supernatants were then collected and TNF-α 
levels were then measured using ELISAs. It is clear that there is only a slight 
increase in TNF-α concentration in the FEP neuroleptic-naïve patients compared 
to the healthy controls, and was not statistically significant (Control: 71.1±13.2 
pg/mL; Schizophrenia: 87.9±20.4 pg/mL). Samples were diluted 1:50 to be in the 
detection range for ELISA analysis. One outlier was detected in each condition 
(ROUT test (1%)) and subsequently removed from analysis. Error bars represent 
± SEM. 
 
 
It is apparent that there is a small increase in the mean TNF-α release from FEP patients 
compared to the matched controls. However, there is wide distribution within the data and 
statistical analysis showed this increase to be non-significant.  
 
 
4.8 TNF-α Concentration According to Patient Demographics 
Results obtained from measuring monocyte TNF-α concentration from each patient was 
sorted according to patient demographics such as smoking status, age, gender and body mass 
index (BMI), seen in figure 14.  
 
Patient smoking status showed a significant (p=0.02) increase in TNF-α concentration 
amongst smokers compared to those who were non-smoking (figure 13 (i)). Gender also 
appeared to be a determinant of TNF-α release amongst schizophrenia patients (figure (ii)). It 
is apparent that males have a higher TNF-α release than females, however this was not 
significant as more female samples are required. Patient age was also considered and it is 
clear that there is an increase in TNF-α in age categories 24-29 and over 30 years old, 
however large patient variability is seen (figure (iii)). Patient BMI was also accounted for, and 
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TNF-α release was increased in patients who were overweight, however again there is large 
variability within the data and is therefore not significant (figure (iv)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: TNF-α release from 9 FEP neuroleptic-naïve schizophrenia 
patients according to smoking-status, gender, age and BMI. TNF-α levels 
from FEP schizophrenic patients were classified according to 4 categories, which 
are often not controlled for in many published studies. (i) Patient smoking 
status. The smoking status of patients was seen to affect the TNF-α release from 
monocytes. A significant increase (p=0.02) in TNF-α release from patients who 
were smokers compared to those who were non-smokers (Non-smoking: 51.8±6.8 
pg/mL; Smoking: 160.0±29.3 pg/mL). (ii) Patient gender. Male patients had 
increased TNF-α release compared to the female patient however was not 
significant as more female patients would need to be sampled. (Male: 91.4±22.8 
pg/mL; Female: 60.0 pg/mL). (iii) Patient age. Patients were separated into 3 age 
categories and TNF-α levels are seen to increase with age. However this 
(i) (ii) 
(iii) (iv) 
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observation was not significant due to large variability between patients (18-23 
years: 66.6±11.9 pg/mL; 24-29 years: 94.9±67.7 pg/mL; >30 years: 134.2±75.1 
pg/mL). (iv) Patient body mass index. Patients were separated into categories, 
which are used to classify body mass index. From the data, an increase in TNF-α 
levels was seen in the overweight category, however this was not significant due 
to large patient variability (Underweight: 67.4±21.4 pg/mL; Healthy: 48.9±21.7 
pg/mL; Overweight: 143.7±44.4 pg/mL; Obese: 60.0 pg/mL). Error bars represent 
±SEM. 
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5. DISCUSSION 
 
5.1 LPS-Stimulation of THP-1 Cells  
 
THP-1 monocytic cells were chosen in this project to provide a cell culture model, to 
represent primary monocytes, which are often difficult to obtain. There are many additional 
advantages to using THP-1 cells over primary monocytes. THP-1 cells have a uniform genetic 
background, therefore removing any donor variability within results as well as removing the 
risk of any common blood contaminants, such as lymphocytes, which can occur in monocyte 
preparations
[63]
. Furthermore, studies have shown that THP-1 cells have a similar 
transcriptional response to monocytes and macrophages, obtained from donor peripheral 
blood, when stimulated with LPS
[63]
. Therefore these cells were chosen to characterise TNF-α 
response in the presence of a range of pharmacological agents. 
 
To obtain the optimal TNF-α release from LPS-stimulated THP-1 cells to be in the ELISA 
detection range, a LPS-stimulation time course was conducted with varying concentrations of 
LPS (figure 7). Application of 100 ng/mL LPS produced the highest TNF-α response 
(508.4±86.6 pg/mL) compared to lower concentrations. Interestingly, the TNF-α 
concentration release from THP-1 cells peaked at 4 hours of LPS stimulation in all conditions 
where a response was elicited. After 4 hours, TNF-α was seen to reduce and after 24 hours, 
TNF-α production had decreased to low levels (96.3±44.9 pg/mL). TNF-α is known to be a 
primary moderator of the innate immune response and rapidly released in response to LPS 
stimulation
[64]
, which these data reiterate. These results are also consistent with those in the 
literature
[63]
. Consequently from these results, a 4-hour stimulation period was chosen to use 
in THP-1 LPS stimulation experiments. 
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This experiment could be repeated in primary monocytes to see if the same TNF-α release 
pattern would be observed therefore providing validity to this in vitro model. Additionally, a 
TNF-α expression time course could be conducted in primary monocytes obtained from 
schizophrenia patients to see if there are any abnormalities in TNF-α release over time and 
whether there is a sustained increase in TNF-α, which could potentially contribute to the 
inflammatory phenotype seen in patient blood.  
 
5.2 TNF-α Production Related to Administration of Pharmacological Agents 
A variety of pharmacological compounds were incubated with THP-1 cells for 4 hours to 
observe any alterations in TNF-α production and release. These drug concentrations were 
chosen as they had been previously used in the laboratory and shown to be optimum 
concentrations however following the preliminary results presented in this study, then it 
would be prudent to re-calculate concentration curves for these drugs under the specific 
conditions used in these experiments.  
 
Results show that upon application of 30 µM 4BP-TQS, TNF-α levels were significantly 
decreased upon stimulation with 10 ng/mL (p=0.002) and 100 ng/mL LPS (p=0.0001) for 4 
hours, compared to the vehicle control (figure 8). 4BP-TQS has been shown to be a potent 
agonist of α7-nAChRs[65, 66]. Traditionally, endogenous ligands and agonists bind to the 
receptors binding site (orthosteric site). However, it has been shown that nAChRs also contain 
multiple additional binding sites (allosteric sites)
[27]
. Molecules that bind within this site 
typically exert their activity only if an agonist is bound at the orthosteric site, and can 
indirectly modulate receptor activity by either enhancing or reducing agonist activity
[27, 67]
. 
Positive allosteric modulators (PAMs) act to positively enhance and amplify agonist response, 
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whereas negative allosteric modulators (NAMs) act to reduce the response. When bound to 
the allosteric site in the absence of an agonist, allosteric modulators exhibit no effect on 
receptor activity
[68]
. 
 
4BP-TQS however, has been previously shown to bind to this allosteric site on α7-nAChRs 
and can exert potent agonist activity in the absence of endogenous ligands, inducing a direct 
effect on receptor activity
[65, 66]
. The data (figure 8) confirms that activation of the nAChR 
inhibits pro-inflammatory cytokine release from THP-1 cells following LPS-stimulation. 
Additionally, this effect can be induced not only through orthosteric ligands, such as nicotine 
but can also be regulated in absence of agonist binding, providing an alternative mechanism 
of regulation. This potentially provides a novel mechanism, which could be exploited for 
therapeutic use.  
 
From the cell viability results (figure 11), it is apparent that 4BP-TQS is not toxic to THP-1 
cells even at high concentrations (100 µM). However, it is apparent from the incubation with 
25 µM cycloheximide, a protein synthesis inhibitor, that this toxic compound did not kill the 
THP-1 cells as expected.  This could be because the 4-hour incubation was too short to do 
significant damage to THP-1 cell viability. Therefore this experiment could be repeated with 
longer incubation time of over 24 hours to check that 4BP-TQS does not affect cell viability 
over a longer stimulation period. 
 
Additional experiments with 4BP-TQS could be conducted using monocytes harvested from 
donors to see if this nAChR allosteric agonist can elicit the same effect seen in this in vitro 
  44 
model. Furthermore, it should be repeated with monocytes harvested from schizophrenia 
patients to see if 4BP-TQS can reduce the elevated pro-inflammatory response. 
 
LPS-stimulated THP-1 cells were also incubated with a combination of nAChR allosteric 
modulators, PNU-282987 and PNU-120596 (PAM). It can be seen from the results that TNF-
α release was significantly decreased when stimulated with 100 ng/mL LPS for 4 hours 
compared to the vehicle control. PNU-282987 is a selective and potent agonist of the α7 
subtype of nAChRs
[69]
 whose activity is enhanced in the presence of PNU-120596, a selective 
α7 PAM[27]. This result therefore reinforces that TNF-α release from THP-1 cells can be 
altered through manipulation of α7-nAChRs. However, reduction in TNF-α upon incubation 
with PNU and PAM was not as prominent as observed by application of allosteric agonist 
4BP-TQS and, upon normalisation of the data, considerable variability was seen between 
experiments involving PNU and PAM incubation (figure 8 (iv)). Therefore to obtain a firm 
conclusion, more replicates are required. Interestingly, PNU-282987 has been shown to 
restore sensory gating deficits in vivo
[27]
 and so this compound could potentially provide a 
treatment aimed to target cognitive effects of schizophrenia, as well as reducing inflammatory 
response. 
 
Incubation with 5-HT and a potent 5-HT3 receptor allosteric modulator
[70]
, 5-Chloroindole 
showed a small but insignificant decrease in TNF-α release when stimulated with 10 and 100 
ng/mL LPS compared to the vehicle control (figure 8 (i) and (iii)). Serotonin is a monoamine 
neurotransmitter known to be involved in many neurological processes including learning and 
memory, mood
[71]
 and has been heavily implicated in treating depression. Therefore, 5-HT 
derived treatments have been used to relieve the negative symptoms associated with 
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schizophrenia
[72, 73]
. In this experiment, 5-HT was used to investigate whether this compound 
may also have an effect on the inflammatory response, however the data suggest that it does 
not.  
 
THP-1 cells were also incubated with clozapine, an atypical anti-psychotic given to 
schizophrenic patients that have not responded to other treatments. Clozapine is a broad-
spectrum antagonist known to bind to many dopaminergic, serotoninergic and GABA 
receptors
[74]
 and has been shown to reduce many negative symptoms of schizophrenia 
including depression through antagonism of the 5-HTA receptor
[72]
. Studies have shown that 
clozapine can actually increase the plasma levels of TNF-α[75]. Within this experiment 
clozapine was administered at a concentration found within patient plasma. The data (figure 
8) appear to show a small decrease in TNF-α release compared to the vehicle control. 
Clozapine however is known to have many adverse side effects such as agranulocytosis and 
seizures and is predominately linked with weight-gain in medicated individuals
[50, 75]
. It is 
therefore believed that this increase in cytokine levels could be associated with increased 
weight and therefore may explain why elevated levels were not seen within this model. 
Because clozapine has shown mixed results in its ability to reduce pro-inflammatory 
cytokines in addition to its severe side-effects, it is therefore suggested that research into 
treatments involving α7-nAChR agonists should be prioritised. Current investigations show 
promising α7-nAChR treatments such as GTS-21 (DMXBA)[76, 77] which has shown to 
improve cognition and the P50 deficit in clinical trials, however these compounds require 
further investigation since the drug has a relatively short half-life, so would require frequent 
dosage
[77]
 which would be unrealistic for patients. 
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5.3 Inhibition of 4BP-TQS Induced TNF-α Reduction. 
Further to the discovery that 4BP-TQS significantly reduced TNF-α release from LPS-
stimulated THP-1 cells, experiments were performed to investigate whether this reduction 
could be blocked using nAChR antagonists and to confirm TNF-α release was via α7-
nAChRs.  
 
Picrotoxin has been previously shown to be an effective inhibitor of the α7 nAChR subunit[78]. 
PTX is a known potent neurotoxin and a channel blocker of many ligand-gated ion channels, 
including nAChRs
[78]
. Figure 9 shows that the addition of 0.3, 1 and 3 µM of PTX was not 
able to inhibit reduction of TNF-α from THP-1 cells and concentrations were similar to those 
seen with 4BP-TQS alone. However, upon normalisation to the vehicle control, it is apparent 
that there is considerable variation between experiments and it is advised that more replicates 
are conducted. Additionally, higher concentrations of PTX could be needed however could 
not be investigated due to project time constraints.  
 
Methyllycaconitine is a potent competitive orthosteric antagonist of α7-nAChRs[79]. The data 
(figure 12) demonstrate that the application of 10 µM 4BP-TQS is able to reduce the TNF-α 
levels, as previously documented. In comparison, upon application of MLA and 4BP-TQS, 
there is an increase in the production of TNF-α. Upon normalisation to the vehicle control for 
each condition, it is clear that MLA causes a marked increase in TNF-α levels, suggesting that 
antagonist activity of MLA, in combination with 4BP-TQS, is increased. When MLA is 
applied to LPS-stimulated cells however, there is a significant decrease (p=0.05) in TNF-α 
levels, which contradicts the hypothesis that MLA should antagonise the nAChR anti-
inflammatory response. However, upon normalisation of the data compared to the vehicle 
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control, considerably large variability is evident and therefore more replications are needed 
before a definitive conclusion can be drawn.  
 
5.4 TNF-α Release from LPS-Stimulated Monocytes From Neuroleptic-Naïve FEP 
Patients.  
5.4.1 TNF-α Concentration From FEP Neuroleptic-naïve Monocytes Compared to Healthy 
Controls. 
This investigation is one of the few to quantify TNF-α release from LPS-stimulated 
monocytes from 10 FEP, neuroleptic-naïve patients which have been controlled for 
demographics such as age, gender, BMI and smoking-status. This study provides a significant 
benefit over previous investigations as these studies have failed to control for such factors that 
would produce erroneous measurements of TNF-α. As such, previous research is unlikely to 
represent an accurate and realistic picture of the role of inflammatory cytokines in 
schizophrenia cases. 
 
Figure 13 shows TNF-α release from 8 control individuals compared to levels obtained from 
9 FEP patients (an outlier from each condition had been statistically removed). It is apparent 
that there is a small increase in TNF-α amongst patients, however this was not significantly 
different when compared to the controls. This suggests that when cytokine status is 
investigated at the first onset of schizophrenia, before commencing medication, that there is 
no significant increase in pro-inflammatory cytokines and that the increases in TNF-α 
concentrations seen in the literature are potentially due to medication or sampling from 
patients at a different stage in disease course. Additionally, these results are obtained from a 
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single-cell population of monocytes, and an increase in TNF-α could be apparent in the serum 
or plasma obtained from these patients, which has been shown in the literature. 
 
Future investigations should initially measure TNF-α levels from plasma obtained from these 
FEP patients and control individuals to test whether TNF-α is elevated, as reported in the 
literature. Other pro-inflammatory cytokines, such as IL-6, released from monocytes have 
been shown to be more consistently elevated in schizophrenia studies
[41, 80]
. Future 
experiments should therefore assess whether concentrations of these cytokines are elevated in 
FEP neuroleptic-naïve patients compared to healthy controls. A Luminex multiplex assay 
should also be performed to investigate levels of numerous pro-inflammatory, and anti-
inflammatory cytokines simultaneously from both monocyte and serum preparations. From 
these results, certain cytokines of interest, providing a better model for the inflammatory 
response associated with schizophrenia, could then be investigated further. 
 
5.4.2 TNF-α Release From FEP Neuroleptic-naïve Patients According to Demographic 
Factors. 
Once TNF-α levels had been measured for both controls and patients, the sample identities 
were revealed, and the patient data was categorised according to smoking status, gender, age 
and BMI (figure 14). It is clear that patients who smoked nicotine had a significant increase 
(p=0.02) in TNF-α release. This data appears contradictory to the phenomenon of nicotine 
agonism of nAChRs, which produces a reduction in pro-inflammatory cytokines. A possible 
explanation for this is that if these patients are chronic smokers, then the overall pro-
inflammatory response could be elevated since nicotine has many other adverse side-effects 
that contribute to the inflammatory response (e.g. cardiovascular and respiratory 
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complications). Furthermore, Van der Zanden et al. (2012)
[81]
 have shown that LPS-
stimulated THP-1 monocyte release was inhibited by nAChR activation however was not 
constantly observed in primary monocytes from smoking individuals, which suggests that 
patient variability could play a role in this unpredicted response. Therefore for further 
investigation, it is advised that the sample numbers be increased for both the FEP patients and 
control individuals to provide a better representation of the population and aid in the omission 
of anomalous data. 
 
None of the other schizophrenia patient demographics produced any significant differences in 
TNF-α release however an increase in BMI was seen to elevate TNF-α levels suggesting that 
BMI does play a role in the increase of pro-inflammatory cytokines of patients. However 
large variability was seen amongst patients and further data would be required to be able to 
draw any definitive or firm conclusions. This data needs to be compared with data obtained 
from the demographically controlled healthy individuals to provide a true comparison. 
Unfortunately this data could not be made available at the time of writing. 
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6. CONCLUSION 
The data presented in this study represent a substantial development in our ability to 
investigate the role of pro-inflammatory cytokines in the development of schizophrenia. An 
abnormal increase in pro-inflammatory cytokines, such as TNF-α, can hinder both the early 
development of the brain and periods of neuronal plasticity in later life leading to an increased 
risk of schizophrenia. Many studies have documented an elevated release of TNF-α in 
schizophrenia patients however there is a certain amount of ambiguity within these studies as 
others have claimed no significant difference. It is believed that these discrepancies are likely 
to be as a result of a failure on behalf of these investigations to control for factors that can 
affect cytokine concentrations, such as medication. This study therefore aimed to remove this 
uncertainty in TNF-α determination in schizophrenia and is one of the few studies to 
investigate TNF-α release from primary monocytes from neuroleptic-naïve FEP patients who 
had been demographically matched to healthy controls. The subsequent findings show a small 
increase in TNF-α release from 9 FEP patients although was not statistically significant when 
compared to 8 healthy controls.  It is recommended however that the sample size be increased 
to provide a better representation of the population.  
 
In addition to these results, it was discovered that the nAChR allosteric agonist, 4BP-TQS 
was significantly able to reduce TNF-α from THP-1 monocytes. Further research needs to be 
conducted into whether this compound could potentially be adapted to provide a treatment 
targeted at reducing the inflammatory response that affects the positive, negative and 
cognitive symptoms seen in schizophrenia. Nicotine, a principal agonist of the nAChRs, is 
widely used among schizophrenic patients for this purpose, however this study showed that 
TNF-α release was significantly increased amongst smokers, suggesting that prolonged 
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nicotine usage can actually have the opposite effect. Consequently, it would be beneficial to 
further research additional nAChR agonists to remove these adverse effects apparent in self-
medicalization treatments and currently prescribed anti-psychotics, such as clozapine.  
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